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ASSOCIATION OF HLA-A AND B ALLELES WITH ANTIEPILEPTIC DRUG-
INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS IN A 
MULTI–ETHNIC MALAYSIAN POPULATION 
 
ABSTRACT 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a type 
of severe cutaneous adverse drugs reaction, are an immune-mediated hypersensitivity 
reaction. Common high risk drugs causing SJS and TEN are aromatic antiepileptic 
drugs (AEDs) particularly Carbamazepine (CBZ), Phenytoin (PHT) and Lamotrigine 
(LTG). CBZ is a widely prescribed first-line treatment for epilepsy in Malaysia and 
therefore is the main causal drug for SJS/TEN cases. A strong association was 
discovered between HLA-B*15:02 and CBZ-induced SJS/TEN in Taiwan Han Chinese, 
subsequently the association was replicated in other populations in Southeast Asia 
including Hong Kong, China, Thailand, Vietnam, India and Malaysia. Malaysia 
population is composed of heterogeneous multi-ethnic demographic from Austronesia 
(Malay), Southern India and Southern China. Studies from Malaysia reported the 
association in Malay and Chinese ethnic groups with one study on Malay CBZ-
SJS/TEN that found HLA-B*15:02 in 75% of the cases compared to 15.7% in general 
Malay population. While another study included a mixture of Malay and Chinese CBZ-
SJS/TEN cases all of which were positive for HLA-B*15:02 but without appropriate 
drug tolerant control. Furthermore, no study was performed in Malaysia’s Indian ethnic 
group. Ethnicity specific HLA-A and -B allele association conferring susceptibility to 
CBZ, PHT and LTG-induced SJS/TEN was investigated in Malaysia three major ethnic 
groups in this study. AEDs-SJS/TEN cases and AEDs tolerant controls were recruited 
from two hospitals across Malaysia and HLA-A and -B genotyping were performed. The 
carrier frequencies of specific HLA-A and -B alleles were compared between 36 AEDs-
SJS/TEN cases and 273 AEDs-tolerant controls, stratified by ethnicity and causal drugs. 
Significant association between HLA-B*15:02 and CBZ-SJS/TEN was detected in the 
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three major ethnic groups: Malay (87.5% versus 12.5%; p = 2.00 x 10-8; Odds ratio 
(OR) = 49.0; 95% confidence interval (CI) = 9.4-256.8), Chinese (66.7% versus 12.3%; 
p = 0.0047; OR = 14.3; 95% CI = 2.4-86.0) and Indian (33.3% versus 3.5%; p = 0.042; 
OR = 13.8; 95% CI = 1.5-125.0). Combined analysis of all ethnic groups showed a 
significant association with ORCMH of 26.6 (95% CI 12.8-55.3; PCMH = 2.31 x 10-26). For 
HLA-A, association of HLA-A*31:01 with CBZ-SJS/TEN was discovered in Indians for 
the first time (p = 0.023; OR = 10.4; 95% CI = 1.6-65.8). This allele was not found in 
Malay and Chinese CBZ-SJS/TEN groups. Logistic regression analysis demonstrated 
that HLA-A*31:01 has an independent effect after conditioning for HLA-B*15:02 (P = 
0.019; OR 11.7; 95% CI 1.5-9.1). No association was found in PHT and LTG-SJS cases 
for the three ethnic groups, probably due to limited sample size. In conclusion, this 
study replicated the association between HLA-B*15:02 and CBZ-SJS/TEN in Malay, 
Chinese and Indian populations in Malaysia and further demonstrated a new association 
between HLA-A*31:01 and CBZ-induced SJS/TEN in Indians.  
 
Keywords: Severe cutaneous adverse drug reactions, Stevens-Johnson syndrome and 
toxic epidermal necrolysis, human leukocyte antigen allele.  
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ASOSIASI ANTARA ALEL HLA-A DAN B DENGAN REAKSI KULIT TERUK 
AKIBAT UBAT ANTI-EPILEPTIK DI KALANGAN POPULASI MALAYSIA 
YANG BERBILANG ETNIK  
 
ABSTRAK 
 Sindrom Stevens-Johnson (SJS) dan nekrolisis epidermis toksik (TEN), sejenis 
reaksi kulit teruk akibat ubat, adalah hypersensitiviti yang disebabkan sistem imun. 
Ubat penyebab umum yang berisiko tinggi mengakibat SJS dan TEN ialah ubat anti-
epileptik aromatik (AEDs), terutama Carbamazepine (CBZ), Phenytoin (PHT) dan 
Lamotrigine (LTG). CBZ adalah ubat barisan pertama untuk epilepsi yang digunakan 
dengan meluas di Malaysia, oleh sedemikian ubat ini penyebab utama dalam kes 
SJS/TEN. Asosiasi yang kukuh telah ditemui di antara HLA-B*15:02 dan CBZ- 
SJS/TEN di kalangan Taiwan Han China. Asosiasi ini juga dikesani berulang dalam 
populasi lain di kalangan Asia tenggara, termasuk Hong Kong, China, Thailand, 
Vietnam, India and Malaysia. Populasi Malaysia terdiri dari demografi heterogen yang 
berbilang etnik seperti Austronesia (Malayu), Cina selatan dan India selatan. Kajian dari 
Malaysia melapor asosiasi di kumpulan etnik Malayu dan Cina. Salah satu kajian 
mengesani HLA-B*15:02 dalam 75% kes Melayu CBZ-SJS/TEN berbanding dengan 
15.7% di kalangan populasi Melayu umum. Manakala satu kajian Malaysia yang 
meliputi campuran kes CBZ-SJS/TEN Melayu dan Cina mendapati semua pesakit 
positif kepada HLA-B*15:02, tetapi kajian ini kekurangan pesakit kawalan toleran yang 
sesuai. Tambahan pula, tidak ada kajian Malaysia yang menyelidik asosiasi di kalangan 
kumpulan etnik India. Alel-alel HLA-A dan -B dalam etnik tertentu berkaitan dengan 
kecenderungan mendapat CBZ, PHT dan LTG-SJS/TEN. Oleh sebab itu, faktor etnik 
adalah kemestian penting yang perlu dilitupi dalam kajian ini. Kes AEDs-SJS/TEN dan 
kawalan toleran AEDs direkrut dari dua hospital di Malaysia dan penjenisan genotip 
HLA-A dan -B dilaksanakan. Frekuensi pembawa alel HLA-A dan -B dibanding antara 
36 kes CBZ-SJS/TEN kes dan 273 kawalan tolerant AEDs dan analisis berstrata 
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dijalankan berasas faktor etnik dan ubat penyebab. Asosiasi signifikan antara HLA-
B*15:02 dan CBZ-SJS/TEN dikesan dalam ketiga-tiga kumpulan etnik: Melayu (87.5% 
lawan 12.5%; p = 2.00 x 10-8; Nisbah Ods (OR) = 49.0; 95% Selang Keyakinan (CI) = 
9.4-256.8), Cina (66.7% lawan 12.3%; p = 0.0047; OR = 14.3; 95% CI = 2.4-86.0) dan 
India (33.3% lawan 3.5%; p = 0.042; OR = 13.8; 95% CI = 1.5-125.0). Analisis 
gabungan ketiga-tiga kumpulan etnik menunjuk hubungan signifikan ternyata dengan 
ORCMH 26.6 (95% CI 12.8-55.3; PCMH = 2.31 x 10-26). Asosiasi antara alel HLA-
A*31:01 dan CBZ-SJS/TEN di kalangan India dikesani pertama kali (p = 0.023; OR = 
10.4; 95% CI = 1.64-65.8). Alel ini tidak dapat dikesani di kalangan kes Melayu dan 
Cina CBZ-SJS/TEN. Asosiasi tidak dapat dikesani dalam ketiga-tiga kumpulan etnik 
kes PHT and LTG-SJS kemungkinannya disebabkan oleh kekurangan saiz sampel. 
Kesimpulan, kajian ini mengulangi asosiasi antara HLA-B*15:02 and CBZ-SJS/TEN 
dalam kalangan populasi Melayu, Cina dan India di Malaysia dan juga mengesani 
kaitan baru antara HLA-A*31:01 and CBZ- SJS/TEN di kalangan India. 
 
Kata kunci: reaksi kulit teruk oleh ubat, sindrom Stevens-Johnson, nekrolisis epidermis 
toksik, alel antigen leukosit manusia 
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CHAPTER 1: INTRODUCTION 
 
 Severe cutaneous adverse reactions (SCARs) to drugs are a type of delayed 
hypersensitivity reaction that is idiosyncratic, unpredictable and dose-independent. 
SCARs account for 15-20% of all adverse drug reactions (Thong & Tan, 2011). It 
includes Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which 
are characterized by blistering and erosion of skin and mucous membrane due to 
necrosis of keratinocytes. Although SJS and TEN are rare, it is associated with 
mortality rate as high as 5-15% and 40%, respectively (Roujeau et al., 1995). Another 
phenotype of delayed hypersensitivity reactions is drug reaction with eosinophilia and 
systemic symptoms (DRESS), which involved systemic organs. A milder form of 
cutaneous drug eruption (rash) is maculopapular exanthema (MPE) (Harr & French, 
2010; Nayak & Acharjya, 2008). 
 One of the high-risk drugs in causing SJS/TEN are aromatic antiepileptic drugs 
(AEDs), Carbamazepine (CBZ), Phenytoin (PHT) and Lamotrigine (LTG). CBZ is a 
widely prescribed first-line treatment for epilepsy in Malaysia and hence the main 
causal drug for SJS/TEN cases (Choon & Lai, 2012; Thong & Tan, 2011). Population 
study from RegiSCAR group reported the risk of SJS/TEN in CBZ user as 1.4 per 
10,000 new users (Mockenhaupt et al., 2005). 
 An important progression has been the discovery of the association of HLA 
alleles and these SCAR syndromes. The findings of HLA association have shed light on 
the predisposing genetic risk factor in SCARs and provide a means for prevention by 
screening prior to drug treatment. In line with the emerging approach of precision 
medicine where prescribed treatment takes into consideration individual genetic 
variability.  
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 Identifying the type of SCARs is important for identifying the HLA alleles 
associated with this hypersensitivity syndrome (Phillips et al., 2011). In SJS/TEN cases 
induced by Carbamazepine, strong association was discovered to HLA-B*15:02 in 
Taiwan Han Chinese, subsequently the association was replicated in different 
populations across Asia, such as Thai, Vietnamese, Han Chinese from Hong Kong and 
Mainland China, Malays in Malaysia, west central Indians and northern Indians from 
India but with various effect size (Chang et al., 2011; Cheung et al., 2013; Chung et al., 
2004; Mehta et al., 2009; Nguyen et al., 2015; Tassaneeyakul et al., 2010; Then et al., 
2011; Wu et al., 2010). The association of HLA-B*15:02 was extended to phenytoin and 
lamotrigine-induced SJS/TEN, although the strength of association is not as strong as 
found in CBZ-SJS/TEN. The associations between HLA-B*15:02 and SJS/TEN 
secondary to phenytoin and lamotrigine were only reported in Han Chinese and Thai 
populations and remains unknown in other ethnicity (Cheung et al., 2013; Locharernkul 
et al., 2008). It became apparent that the exclusivity observed between HLA-B*15:02 
association to CBZ-SJS/TEN was specific to phenotype, ethnicity and to some extend 
the culprit drug.  
 The association between HLA-B*15:02 and CBZ-SJS/TEN was not detected in 
Japanese, Koreans and Europeans. Instead, in Japan and Korea, CBZ-SJS/TEN was 
reported to be associated with HLA-B*15:11 (Kaniwa et al., 2010; Kim et al., 2011; 
Ozeki et al., 2011). Interestingly, both HLA-B*15:11 and HLA-B*15:02 belongs to the 
same B75 serotype subfamily. Recently, HLA-A*31:01 allele was found in association 
with all phenotypes of CBZ-induced hypersensitivity reactions (including SJS/TEN, 
DRESS and MPE) in Japanese and Europeans (McCormack et al., 2011; Ozeki et al., 
2011). However, later on meta-analysis study contradicted it, in which HLA-A*31:01 
was more strongly associated with CBZ-DRESS than CBZ-SJS/TEN in Han Chinese 
and Europeans (Genin et al., 2014). In Japanese, the association of HLA-A*31:01 to all 
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CBZ-hypersensitivity is confirmed in 2 more case-control studies (Kashiwagi et al., 
2008; Niihara et al., 2012). Overall, these studies confirmed the association between 
HLA-A*31:01 and CBZ-DRESS, but the association to CBZ-SJS/TEN and MPE is 
inconsistent.  
 The presence of multiple risk alleles in different ethnicity confer the need to 
investigate risk variants relevant to our population. Although two studies have 
investigated the association of HLA-B*15:02 and CBZ-induced SJS/TEN in Malay and 
Chinese ethnic group in Malaysia, the sample sizes are small and appropriate ethnic-
specific drug tolerant controls was not employed (Chang et al., 2011; Then et al., 2011).  
 Malaysia population is made up of three major ethnic groups; with Malays 
forming the largest group (67.4%) followed by Chinese (24.6%), Indians (7.3%) and 
other minorities (0.7%) according to the latest national census. The Malays in Malaysia 
are predominantly of Austronesian and Southeast Asian aboriginal (Proto-Malay) 
ancestries and are genetically similar to Singapore Malays and western Indonesian 
Malays (Deng et al., 2015). Whereas Malaysian Chinese are of Southern Han Chinese 
and Indians mostly originated from Southern India (Basu et al., 2003; Reich et al., 
2009). However, for Indians, the allele frequency of HLA-B*15:02 is not 
homogeneously distributed. HLA-B*15:02 allele frequency in India population ranges 
from 0-6% depending on region, with as low as 0% in west coast Parsi, 1.6% in 
northern Indian, to 4% in west Bhil, and 6% in Pawra in Khandesh region, but not 
available for southern Indian (Gonzalez-Galarza et al., 2015). 
 Recent studies have demonstrated varying HLA allele frequency among different 
ethnicities could influent the susceptibility to drug hypersensitivity reactions (Grover & 
Kukreti, 2014; Yip et al., 2012). To factor in HLA allele frequency of different 
ethnicities, this study stratified the SCARs cases by ethnicity prior to perform the 
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analysis and assessed the possibility of heterogeneity. Furthermore, no study was 
performed in Malaysian Indian ethnic group. 
 The study objectives are: 1) To confirm the association of HLA-B*15:02 allele 
with CBZ, PHT and LTG-induced SCARs; 2) To investigate other ethnicity-specific 
HLA-A and -B allele associated with CBZ, PHT and LTG-induced SCARs in a multi-
ethnic Malaysian population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
5 
CHAPTER 2: LITERATURE REVIEW 
 
2.1 Severe cutaneous adverse drug reactions (SCARs) 
 Severe cutaneous adverse reactions to drugs are a type of delayed 
hypersensitivity reaction that is idiosyncratic, non-predictable and dose-independent. 
SCARs are associated with significant mortality and morbidity, long-term sequelae, 
high healthcare cost and it is a challenge in drug development. There were several drugs 
withdrawal from the market due to association with SCARs (Lasser et al., 2002). 
 SCARs cover a large variety of clinical phenotypes consists mainly of Stevens-
Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with 
eosinophilia and systemic symptoms (DRESS). A milder form of cutaneous adverse 
drug reactions is maculopapular exanthema (MPE), a rash that is mild, self-limited and 
usually resolved after the offending drugs are withdrawn. Unlike MPE, SCARs have 
serious morbidity, involving systemic manifestation and posed high mortality (Thong & 
Tan, 2011). The histopathology of MPE, DRESS and SJS/TEN is predominated with 
exocytosis and lymphocytes and macrophages infiltrate. In severe cases of SJS/TEN, 
extensive keratinocytes necrosis is observed. The severity of inflammatory infiltrate and 
epidermal manifestation increased from MPE to DRESS and SJS/TEN (Duong et al., 
2017).  
 Early diagnosis of SCARs that helps in identification of culprit drugs are 
important in the acute stage of the reactions. A prompt recognition helps to improve the 
management of the disease as it progresses and limit long-term sequelae. Classification 
of SCARs is also important in identifying causal drug. Studies have shown interval 
between drug intake and SCARs onset differ for different SCARs type. SJS/TEN has 
shorter latency time compared to DRESS (Kardaun et al., 2007). Assessment scores and 
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tools were developed to assist in investigation of SCARs to determine clinical patterns 
and identify causal drugs.  
 
2.2 Classification of SCARs  
 The current commonly used classification is Severe Cutaneous Adverse 
Reactions (SCARs) study by Bastuji-Garin S. et al. and validation scores developed by 
a group of SCARs experts, RegiSCAR (Bastuji-Garin et al., 1993). Several studies have 
developed algorithms to assist causality assessment objectively. As a standardised 
approach is important to establish causality for physician to come to an accurate and 
reproducible diagnosis of SCARs. Some of the algorithms developed for drug causality 
assessment in cutaneous adverse drug reactions are Naranjo, the French 
pharmacovigilance causality score test, the RUCAM algorithm and algorithm of drug 
causality for epidermal necrolysis (ALDEN) which is validated for SJS/TEN (Begaud et 
al., 1985; Danan & Teschke, 2016; Naranjo et al., 1981; Sassolas et al., 2010). The most 
widely used algorithm worldwide to identify culprit drugs are Naranjo algorithm and 
the French pharmacovigilance causality score test. ALDEN algorithm is also gaining 
prominence as it is frequently applied in SJS and TEN cases to assess suspected drugs 
(Sassolas et al., 2010).  
 A multinational collaborative research consortium was formed in 1988 to study 
SCARs. The consortium, initially named EuroSCAR, is a European network focusing 
on SCARs that brought together experts from dermatology, genetics, immunology, 
pharmacology and epidemiology. It later changed its name to RegiSCAR when 
expending the scope of diseases and engaging new teams from other countries. The 
scope of SCARs type has been extended from the initial SJS/TEN and DRESS to 
include acute generalized exanthematous pustulosis (AGEP). The RegiSCAR group 
operates as a registry in collecting clinical data and biological samples, provide 
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continuous surveillance on new drugs and guidelines for SCARs. They also aim to 
improve drug safety in order to reduce the medical and economic burden of SCARs in 
public health. To prevent misdiagnosis, RegiSCAR has defined consensus diagnosis 
criteria for each SCAR phenotype. RegiSCAR employed a rigorous systemic approach 
and clear diagnostic criteria to phenotype SCARs. SCARs cases were investigated by 
using standardized questionnaires to obtain detailed information on phenotypes, 
including collecting clinical photograph and skin biopsies, associated medical 
conditions and drug exposure. They reported that causality can be attributed to a dozen 
high risk medications and that misdiagnoses were frequent. Their studies show that 
overlapping SCARs phenotypes were rare. They established that SJS and TEN are 
variants of the same disease, and that SJS/TEN and DRESS are two distinct disease 
(Bastuji-Garin et al., 1993; Kardaun et al., 2007).  Although SJS/TEN and DRESS are 
implicated by the same group of high risk medications. Besides that, there was also the 
difficulty in assessing drug causality due to incomplete reporting of drug exposure. 
From RegiSCAR findings, they constructed a specific algorithm for drug causality, 
algorithm of drug causality for epidermal necrolysis (ALDEN), that are used widely in 
recent SCARs studies (Sassolas et al., 2010). Using the collected data from their study, 
they are able to estimate medication risk, prognosis indexes, disease outcome and 
effects on treatments for SCARs. Other on-going investigations are phenotype 
determination, lymphocytes antigenic specificity and susceptibility genes and single 
nucleotide polymorphisms (SNPs) (Phillips et al., 2011). 
 Generally, for SCARs assessment, it relies mainly on cutaneous manifestation 
and clinical presentation, duration of the eruptions, associated symptoms and latency 
time between starting drug and eruption onset. The distribution and physical 
examination of the skin lesions coupled with skin biopsy for histological testing are all 
important for accurate and quick diagnosis of SJS/TEN, as diagnosis of SJS/TEN within 
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7 days of onset is associated with improved survival. Currently, there is no validated 
curative treatment for SJS/TEN. The standard treatments strategies are symptomatic 
with the aim to prevent long-term sequelae (Duong et al., 2017; Palmieri et al., 2002). 
 
2.2.1 Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN) 
2.2.1.1 Clinical Feature of SJS and TEN 
 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are 
considered variants of different severity from the same disease spectrum. SJS and TEN 
are classified by the extent of body surface area (BSA) with skin detachment. With less 
than 10% of skin detachment as SJS. The most severe forms with more than 30% of 
skin detachment as TEN and between 10-30% skin detachment as SJS/TEN overlap 
(Bastuji-Garin et al., 1993; Roujeau & Stern, 1994). 
 Early stage of SJS/TEN clinical manifestation includes fever, malaise, flu-like 
symptoms, eyes, ear, nose, throat events and skin pain prior to cutaneous manifestations 
by a few days. Symptoms of skin eruption first appears on face, pre-sternal area of 
upper trunk and extremities. The skin eruption is distributed more to the proximal part 
of the extremities while the distal part is relatively spared (Auquier-Dunant et al., 2002). 
 Cutaneous manifestations in SJS and TEN are characterised by rapid developing 
erythematous or purple-red macules and atypical target lesions with dark centre and 
indistinct border. The skin lesions progress to flaccid blisters and have a tendency to 
rapidly coalesced forming confluent epidermal necrosis, and large epidermal sheet 
detachment. However, if there is absence of obvious epidermal detachment, Nikolsky’s 
sign, characterised by detachment of necrotic epidermis from the dermis under lateral 
mechanical pressure on erythematous zones, can be performed (Duong et al., 2017; Harr 
& French, 2010). 
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 In 80% of the case, haemorrhagic erosion of two or more mucous membranes 
preceding skin eruption occurs, usually in eyes, mouths, nasopharynx or genitalia. The 
haemorrhagic erosion in mouth has a greyish-white pseudo-membrane coating. Lesions 
occurring in eyes cause chemosis, hyperaemia, photophobia and erosions. In severe 
cases, it leads to ulceration in the corneal. However, it is noted that the severity of acute 
phase in ocular manifestation does not predict late phase complications. Common organ 
involvements associated with SJS and TEN are liver and kidney enzymes elevation and 
necrotic lesions in epithelial of bronchial and gastrointestinal track. Up to 73% of 
patients suffered long-term sequelae from mucosal involvement of oesophageal, lung 
and genital mucosa. In TEN patients, up to 50% develop long term ocular 
complications. Severe dry eyes and ingrowth of eyelashes are two of the most common 
complications (Harr & French, 2010; Magina et al., 2003; Yip et al., 2007),  
 
2.2.1.2. Diagnosis of SJS and TEN 
 There is no specific diagnostic test for SJS and TEN. The diagnosis is based on 
clinical symptoms, cutaneous manifestation and histological test. In acute phase, to 
enable rapid diagnosis, histological examinations such as direct immunofluorescence 
analysis are usually performed on cryosection of the skin. This helps to exclude 
differential diagnosis of similar disease such as bullous fixed drug eruption, 
autoimmune blistering diseases, acute generalized exanthematous pustulosis (AGEP) 
and staphylococcal scalded skin syndrome, a rarer form of cutaneous manifestation in 
adults. A negative direct immunofluorescence test and full-thickness epidermal necrosis 
are mandatory signs for SJS/TEN diagnosis. A negative direct immunofluorescence test 
that show absence of immunoglobulin or complement deposit in the epidermis or 
dermal layer is used to rule out autoimmune blistering diseases (Harr & French, 2010). 
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After SJS/TEN diagnosis is established, prompt identification and withdrawal of the 
causative drug is important.  
 
2.2.2 Drug reaction with eosinophilia and systemic symptoms (DRESS) 
2.2.2.1 Clinical Feature of DRESS 
 Drug reaction with eosinophilia and systemic symptoms (DRESS) was first 
described in 1996. It is also known as drug-induced hypersensitivity syndrome. DRESS 
is notorious to diagnose due to its heterogeneous clinical presentation and organ 
involvement with or without cutaneous manifestation (Kardaun et al., 2013). In the 
initial stage, fever, flu-like symptoms, lymphadenopathy, pruritus and burning pain can 
be seen preceding skin eruption up to 2 weeks. Cutaneous manifestation involve 
erythroderma, purpura, pustules, swelling of face and distal extremities. The organ 
involvement in DRESS symptoms are from the infiltration of specific eosinophils and 
lymphocyte into the tissues. Liver is the most frequently affected organ in DRESS. 
More than 80% of DRESS cases have liver involvement, seen as hepatic cytolysis and 
cholestasis or in rare case fulminant hepatic failure. Kidney involvement is manifested 
by interstitial nephritis. Respiratory system is affected in up to 15% of DRESS cases, 
characterised by cough, dyspnoea, eosinophilic pneumonitis and in rare cases, 
respiratory failure. In cardiovascular system involvement, it is manifested by cardiac 
enzyme abnormalities, myocarditis and pericarditis (Choudhary et al., 2013; Duong et 
al., 2017). In rare cases, other visceral organ such as muscle, nerves system and 
pancreas are affected, which complicates prognoses. In the acute phase, to prevent 
misdiagnosis, a few clinical investigations are strongly recommended such as testing for 
blood abnormalities to assess organ involvement, hypereosinophilia, atypical 
lymphocytes and virus reactivation (Duong et al., 2017). There is the complication of 
viral reactivation in DRESS, where the human herpesvirus (HHV) members, HHV6, is 
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most reported. Reactivation of other type of HHV that were reported are Epstein Barr 
virus, HHV7 and cytomegalovirus. The reactivation was observed at 2 to 3 weeks after 
DRESS onset. A long period of relapses is described usually with the reactivation of 
HHV6 during the course of DRESS (Choudhary et al., 2013; Duong et al., 2017).  
 
2.2.2.2 Diagnosis of DRESS 
 The histology features of DRESS are non-specific eczematous lesion, focal 
keratinocytes necrosis, eosinophil, neutrophil and monocytes infiltrate and mild 
vasculitis. Due to the high potential of misdiagnosis, two score have been developed to 
validate DRESS syndrome diagnosis with one of the score systematically assess HHV6 
reactivation. Both these scores enable the validation of DRESS diagnosis without 
cutaneous eruption presentation and recommended to reconsider it as multi-organ drug-
induced reaction (Kardaun et al., 2007; Shiohara et al., 2007). Cutaneous manifestation 
of DRESS is mainly mediated by CD8+ T cells. High level of drug-specific CD8+T 
cells expressing granzyme B was detected in skin biopsy of severe DRESS patients. The 
recruitment of HHV+ peripheral mononuclear cells to damaged skin may have enable 
virus transmission and replication in CD4+ T cells. One study reported that almost half 
of the activated circulating CD8+ T cells from DRESS patients recognised HHV 
whereas the visceral or skin infiltrate CD8+ T cells recognised EBV (Picard et al., 
2010). 
 DRESS has lower mortality (5-10%) compared to SJS/TEN (10-40%). The 
causes of mortality are mainly due to lesions in lungs or myocardium and 
haemophagocytosis. The long-term sequelae seen in DRESS is predominantly of 
autoimmune disease. This excessive autoimmune response is suspected triggered by 
chronic virus reactivation. Corticosteroids treatment has been shown to improve 
autoimmune disease in DRESS patient (Duong et al., 2017).  
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2.3 Epidemiology of SCARs 
 Epidemiology data on SCARs and their causal drugs in Asia is scarce, partly due 
to underreporting of SCARs event and difficulty in definitive diagnosis of SCAR types 
because of overlapping symptoms. Most studies reported on selected population group 
such as hospital inpatient population or specialist allergy and burn centers ( Thong & 
Tan, 2011).  
 Based on studies that focus on cutaneous adverse drug reactions, a few 
prospective studies in hospital-based population have attempted to evaluate the 
incidence and prevalence. A 6-month prospective study in a France hospital reported 48 
cases of inpatient cutaneous adverse drug reactions and the prevalence of cutaneous 
adverse drug reactions was reported as 3.6 per 1000 inpatient. In this group, 57% 
reported maculopapular eruption whereas 2% has SJS/TEN and one third of the cases 
have previous history of drug hypersensitivity. The main drug implicated was beta-
lactam (Fiszenson-Albala et al., 2003). A study on network-based electronic drug 
allergy notification system for inpatient in a general hospital in Singapore reported 210 
cases of drug hypersensitivity from 90910 admissions of which 5.2% has SCARs. They 
estimated the incidence of drug hypersensitivity at 4.2 per 1000 hospitalization. 75% of 
the cases were caused by antimicrobials and antiepileptic drugs (Thong et al., 2003). A 
Korea study based on their mandatory reporting system for immune-mediated drug 
hypersensitivity reactions found 100 new cases of drug hypersensitivity among 55432 
admission. Among this group, 1% has SJS/TEN. They estimated the drug 
hypersensitivity incidence at 1.8 in 1000 hospitalization. The common causal drugs 
were antibiotics (32%) (Park et al., 2008).  
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2.3.1 Epidemiology of SJS and TEN 
 The studies that focus on SCARs particularly SJS and TEN alone are more 
limited. Based on three studies from United States and Europe, incidence for SJS and 
TEN was estimated at 1.4-6 per million person per year (Chan et al., 1990; Thong & 
Tan, 2011). A study based on FDA Adverse event reporting system (AERS) database in 
US reported similar incidence with 1.9 cases per million for TEN (La Grenade et al., 
2005). In a study from a district city in China, the prevalence for SCARs are 0.15 per 
1000 hospitalization for SJS, 0.04 per 1000 hospitalization for TEN and 0.07 per 1000 
for DRESS. The common causal drugs are antibiotics, followed by antiepileptic drugs 
(Li & Ma, 2006). In Taiwan, the incidence of SJS/TEN in Taiwan Han Chinese is 8 
cases per million person-years. For CBZ-induced SJS/TEN incidence, Hung et. al. 
estimated it at 2.5 cases per 1000 new CBZ users based on 5 years retrospective data 
from Chang Gung Memorial Health System (Hung et al., 2005). In a post marketing 
report (2000-2006) by CBZ manufacturer, Novartis, the author reported that CBZ-
induced SJS/TEN was 10 times higher in Asian countries compared to Caucasian 
countries (Farkas, 2007).  
 The incidence of SJS/TEN in this region, Southeast Asia, is still mostly 
undetermined. Most SJS/TEN epidemiology studies are derived from Thailand, 
Malaysia, Singapore and Philippines. In Malaysia, epidemiology data is limited to 
inpatient hospital based population. Two studies reported CBZ as the main causal drugs 
in all SJS/TEN cases (Kamaliah et al., 1998; Khoo & Foo, 1996). Another study 
reporting on a 10-year data from hospital registry shown incidence rate of cutaneous 
adverse drug reactions at 0.86% and SJS/TEN accounted for 30.1%. Carbamazepine is 
also found to be the main causative drugs in SJS/TEN (Choon & Lai, 2012). A different 
study captured data from primary care in a Malaysia general hospital reported the 
prevalence of cutaneous adverse drug reactions at 0.2% out of 69849 patients. Of all the 
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cutaneous adverse drug reactions cases, the most common manifestation is 
maculopapular rash at 22.4%, followed by SJS at 9.7%, while TEN is 4.5% and DRESS 
is 3.7% (Talib et al., 2015). Talib et al. (2015) attributed the prevalence of cutaneous 
adverse drug reactions in their study (0.2%) lower than reported by Choon and Lai 
(2012) (0.86%) due to mild cases not referred for dermatology consultation hence it was 
not captured. 
 
2.4 Main cause of SCARs 
 The cause of SCARs is predominantly drug related (75-85%) (Lee et al., 2013). 
However, in about 15% of SJS/TEN cases, infections have been reported as the cause. 
The most documented non-drug cause of SJS/TEN is Mycoplasma pneumoniae 
infection and Herpes simplex virus reactivation, which is mainly reported in children. 
There are also cases where no obvious cause was identified (Forman et al., 2002; Harr 
& French, 2010).  
 
2.4.1 High risk drug in SCARs 
 Based on population registry of EuroSCAR and the international case-control 
SCARs studies, the majority of SCARs were attributed to a group of common high risk 
drugs such as anti-infective sulfonamides, allopurinol, oxicam-NSAIDs, nevirapine and 
aromatic antiepileptic drugs (AEDs) such as carbamazepine (CBZ), phenobarbital, 
phenytoin (PHT) and lamotrigine (LTG). In this study, I focus on three high risk 
aromatic antiepileptic drugs, carbamazepine (CBZ), phenytoin (PHT) and lamotrigine 
(LTG). Mockenhaupt et. al. conducted a case-control study on hospitalized patients 
investigating the medication risk for inducing SJS and TEN. Interestingly, treatment 
duration is found highly relevant for drugs that have long term medication usage such as 
in the case of AEDs. They observed that risk of drugs to induce SJS or TEN was 
	
15 
confined to the first 4 weeks (4 to 28 days) of drug intake and subsequent declined 
within 8 weeks. The estimated risk associated with these aromatic antiepileptic drugs, 
CBZ, PHT and LTG are 1.4, 8.3 and 2.5 per 10,000 new users respectively. These 
findings have improved the assessment of drug causality in SJS and TEN (Mockenhaupt 
et al., 2005; Mockenhaupt et al., 2008). Similarly, the common high risk drug in 
DRESS (carbamazepine, anti-infective sulfonamides, phenobarbital, and phenytoin) are 
the same as those strongly associated to SJS/TEN. The time interval from drug intake to 
DRESS symptoms onset (index day) is reported to be around 2 to 6 weeks. Prevalence 
of DRESS is estimated at one in 1000 to one in 10,000 of new user of antiepileptic 
drugs (Kardaun et al., 2007). 
 The same group which is part of the RegiSCAR consortium constructed an 
algorithm, ALDEN, that helps to improve drug causality assessment. In the ALDEN 
score attribution part, the common causal drugs for SJS/TEN was categorized based on 
relative risk to SJS/TEN. High risk drugs such as those of AEDs group, carbamazepine, 
phenytoin, phenobarbital and lamotrigine were given higher positive value. While low 
risk drugs were given less value. This attribution score is an important evaluation 
component of the drugs involved and taking into account concomitant drugs that were 
in the patient during SCARs onset (Sassolas et al., 2010). 
 In cases where several concurrent drugs are implicated as possible culprit drug, 
allergological testing are another option in identifying causation. Due to the severity of 
SJS and TEN re-challenge of the culprit drug is not allowed. Patch testing has been 
reported by using dissolving 10% of native drug in petrolatum and taped to the patient’s 
back for assessment at 48-hour and 96-hour exposure. However, patch test has varying 
specificity and sensitivity according to drug type. In vitro tests have been used to 
measure peripheral blood mononuclear cell (PBMC) activity in SCARs patients. For 
example, lymphocyte transformation test (LTT), an in vitro test that measure T-cells 
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proliferation when exposure to the culprit drug, has been reported. But LTT has low 
relevance in SJS/TEN due to low sensitivity (50%) (Kano et al., 2007). 
 Interestingly, different causal drugs are associated with SCARs in different 
countries and population. Nonetheless, high risk drugs identified in EuroSCAR like 
carbamazepine and allopurinol are still the most common high risk drugs to associate 
with SJS/TEN in Asia populations. In a review on SJS/TEN causal drugs in Southeast 
Asia, CBZ and PHT-SJS/TEN made up of 26% of all cases compared to 12% in 
European countries. The differences can be attributed to several factors such as 
variation in prescribing patterns, standard practice, cost of medication, incidence of the 
drug’s main indication and genetic background of the populations (HLA allele 
distribution and polymorphism of metabolizing enzyme) (Lee et al., 2013). 
 
2.4.2. Main Causal Drug of SJS/TEN in Malaysia - Carbamazepine  
 Carbamazepine (CBZ), with the chemical formula of C15H12N2O, is a 
dibenzazepine. It is a tricyclic compound with anticonvulsant, mood stabilising drug 
and specific analgesic indicated for epilepsy, trigeminal neuralgia and psychiatric 
disorders. It is a first-line antiepileptic drug for partial and generalised tonic-clonic 
seizures and has been used since 1965. CBZ acts as a voltage-gated sodium channels 
blocker by binding to activated sodium channels and prevents repetitive firing of action 
potential. It reduces postsynaptic response and blocks post-tetanic potentiation. CBZ 
also functions as an agonist for inhibitory neurotransmitter, GABA (gamma amino 
butyric acid) by decreasing the excitatory neurotransmitter, glutamate. 75-80% of the 
total plasma concentration of CBZ is bound to plasma protein with bioavailability at a 
range of 75–85%. CBZ is almost completely metabolised in the liver with only 5% 
excreted unchanged. The major metabolism route is conversion to carbamazepine 
10,11-epoxide, catalysed by cytochrome P450 enzymes, CYP3A4, CY2C8 and CYP3A5. 
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The minor metabolism route is ring-hydroxylation to 2-hydroxy-CBZ and 3-hydroxy 
CBZ with CYP2B6 and CYP3A4 as the main catalysts. CBZ has autoinduction effect by 
stimulating the transcriptional upregulation of genes involved in its own metabolism, by 
autoinduction of CYP3A4 and CY2C6. CBZ has an initial half-life of 25–65 hours. After 
autoinduction of CBZ is completed around 3 to 5 weeks at a fixed dose regimen, the 
initial half-life of 25-65 hours decreases to 12-17 hours. Adult therapeutic level for CBZ 
is 4 to 12 mg/mL. (Novartis Pharmaceutical Corporation, 2015; Tolou-Ghamari et al., 
2013) 
 
2.5 The HLA System 
 The major histocompatibility compatibility (MHC) complex in human is also 
known as Human Leukocyte Antigen (HLA). The main role of HLA molecules is in 
presenting pathogen derived peptides peptide to T cells and elicit T cell adaptive 
immune response. T cells can distinguish self-peptide from foreign peptide presented by 
HLA molecules. 
 
2.5.1 Structure and function of HLA molecule 
 MHC is located on the short-arm of chromosome 6 (6p21.3) and encodes cell 
surface glycoproteins. MHC is divided into three main class: Class I, II and III. Class I 
is made up of 6 isoforms – HLA-A, B, C, D, E, F and G. HLA class I molecules is 
consisted of a highly polymorphic 43kDA α heavy chain with noncovalent bond to a 
non-polymorphic β2 microglobulin (12kDa) protein whose gene is located on 
chromosome 15. The α chain and β2 microglobulin forms a membrane bound 
heterodimeric glycoprotein anchored to the cell membrane by the α chain. The α heavy 
chain has 3 extracellular domains (α1, α2 and α3) and a cytoplasmic tail. α3 domain 
and β2 microglobulin are proximal to the cell membrane whereas α1 and α2 domains 
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are more distal to the cell.  α1 and α2 domains fold together into anti-parallel β pleated 
sheets on the bottom and flanked on the side by a pair of anti-parallel α helix wall. The 
structure creates a groove where into peptides binds. The endogenous peptides, usually 
8 to 10 amino acid long, are bound in the peptide-binding groove through hydrogen 
bond and ionic interaction from each end of the peptide. Majority of the HLA class I 
polymorphisms are located in the amino acid residues of peptide binding groove. In 
total, the 8 exons spanned around 1089-1101bp and has 362-366 amino acid. HLA class 
I proteins are ligand for CD8+ T-cell receptors (TCR) and killer cell immunoglobulin-
like receptor (KIR) on natural killer cells, and usually present endogenous peptides.  
The endogenous peptides are derived from cytosolic self-antigen or intracellular 
pathogens. HLA class I are expressed on almost all nucleated cells (Choo, 2007; Marsh 
et al., 2000).  
 Class II is made up of 5 isoforms: HLA-DM, -DO, -DP, -DQ and -DR. HLA 
class II has one 33-35 kDa α chain and one 26-28 kDa β chain. Both chains are 
anchored to the membrane. α chain have 5 exons whereas β chain has 6 exons. HLA 
class II also forms a heterodimer with 2 domains from α chain (α1 and α2) and 2 
domains from β chain (β1 and β2). The main role of HLA Class II main role is to 
present extracellular derived peptides to CD4+ T-cells by means of phagocytosis of 
exogenous proteins. HLA Class II molecules are expressed only in immune cells such as 
B-cells, macrophages, monocytes, dendritic cells and T-cells. MCH Class II also 
encodes genes in antigen processing such as Transporter associated with antigen 
processing gene (TAP). The Class III region is located between Class I and II. It 
encodes for gene involved in inflammatory and complement cascade (e.g. TNF, LTA, 
LTB, C2 and C4) and does not encodes any HLA molecules (Choo, 2007; Marsh et al., 
2000).  
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2.5.2 HLA nomenclature 
 The HLA nomenclature is standardized by WHO HLA Nomenclature Committee 
for Factors of the HLA System. It consists of an international committee that standardise 
the nomenclature regularly. The curation and maintenance of sequence are performed 
by IPD-IMGT/HLA database. In recent years, larger number of new alleles were 
reported and many new alleles are still being constantly discovered every year, although 
most alleles reported since 2000 have very low frequencies. The nomenclature 
undergoes radical updating to accommodate this. The naming starts with each locus that 
are followed by an asterisk (HLA-A*). The subsequent allele name length depends on 
the sequence of the allele compared to its nearest relative. All alleles have a 4-digit 
name or first 2 sets of digits and the subsequent digits are assigned only when 
necessary. As illustrated in Figure 2.1, the numbering starts with field 1 - the first pair 
of digits is the allele group (HLA-A*02). Most of the alleles within same group have the 
same serological specificities. Field 2, the second pair of digits, is the subtypes within 
each allele group that differ in their amino acid residues (HLA-A*02:01). These two 
fields are sufficient to distinguish an HLA allele. Field 3’s digits define allele with the 
same protein but has synonymous nucleotide substitutions in the exons (HLA-
A*02:01:01). The last field shows the alleles with nucleotide substitutions in intronic 
regions or 5' or 3' untranslated regions. Each field is separated by a colon. Sometimes, a 
suffix is also added to indicate the protein status such as low expression (L), null (N), 
secreted (S), aberrant (A) and questionable (Q) (Figure 2.1). The alleles are named in 
the order that they are discovered, hence the numbering does not denote how closely 
related the HLA variants are. Usually, for HLA allele to obtain the minimum four-digit 
resolution, complete sequence of exons 2 and 3 for HLA class I, and complete sequence 
of exon 2 for HLA class II is sufficient (Marsh et al., 2000; Marsh et al., 2010).  
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2.5.3 Polymorphism in HLA 
 In human, HLA system is the most polymorphic region. The polymorphisms in 
this region is not widely spread out, but are concentrated in the region encoding the 
peptide binding groove. In the case of HLA Class I, α1 and α2 domains contain variable 
amino acid residues and are the determinant of the antigenic specificities of the 
molecules. Of all the HLA gene, the most polymorphic is HLA-B, which has more than 
4000 alleles (Marsh et al., 2000; Robinson, 2015). 
 The larger number of non-synonymous mutation in the peptide binding groove 
of MHC suggest strong selection. Resistance to disease is also proposed as one of the 
drive for variation in MHC. The high diversification of HLA-B allele is thought to be 
associated with its efficiency in detecting RNA viruses that evolve quicker than DNA 
viruses. The MHC region has been associated with many disease than any other regions 
of the human genome. MHC region is densely clustered with genes and have strong 
linkage disequilibrium that make it hard to pinpoint the exact causative variant and the 
function it has. Even though autoimmune diseases were discovered to associate with 
changes in the groove resides, taking the example of amino acid resides 57 of HLA-
DQB in type I diabetes, it is still not fully understood how polymorphisms in HLA lead 
to peptides in the HLA grooves to mediate autoimmune disease (Trowsdale & Knight, 
2013). 
 Aside from HLA allele association to diseases, its distribution to specific regions 
and extensive polymorphism have been used to infer human migration and genetic 
diversity among different populations. For example, the most polymorphic allele in 
HLA-B locus, the HLA-B*15 allelic lineage has a non-symmetrical distribution in Asian 
population, where the alleles in northeast Asia tend to be more prevalent in global 
population whereas the alleles found in southeast Asian (SAE) population are more 
specific to SEA region. To illustrate: the most common allele in B*15 lineage, HLA-
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B*15:01, is more prevalent in northeast Asia, whereas HLA-B*15:02 is more prevalent 
in the south of Asia spreading southwards into SEA. HLA-B*15:13 is more specific and 
it is observed within the Indonesian archipelago of SEA. The distribution of HLA-
B*15:02 also support the human migratory route into SEA (Di & Sanchez-Mazas, 2011; 
Solberg et al., 2008). 
 
Figure 2.1: Standardized HLA nomenclature. Figure is adapted from Anthony Nolan 
Research Institute (http://hla.alleles.org/nomenclature/naming) (Robinson et al., 2015). 
 
 
2.6 HLA allele: HLA association to SCARs-induced by antiepileptic drugs (AEDs) 
2.6.1 HLA-B association to SJS/TEN-induced by antiepileptic drugs  
 The resemblances of SJS/TEN histopathological changes to allogeneic skin graft 
rejection of graft-vs-host disease elucidate an immunological mediated process 
(Roujeau et al., 1987). This is supported by SJS studies demonstrated findings of 
circulating immune complexes in serum samples and immunoglobulins in the vessels’ 
wall of dermis of SJS patients (Wuepper et al., 1980). Genetic factors in SJS/TEN was 
further corroborated by occurrence of familial SJS in a pair of identical twin both 
caused by the same drugs. The mother and grandfather of the twins also have a history 
of cutaneous eruptions after ingestion of the same drugs. HLA phenotyping found a 
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common haplotype (A29, B44 and DR7) in the family (Fischer & Shigeoka, 1983). 
Immunogenic susceptibility in SJS was further supported by a study on patients with 
ocular lesion of SJS that has a significant increase of HLA-B44 antigen (Mondino et al., 
1982). Taken together, these early studies established the link between HLA and a 
predisposed risk to drug hypersensitivity reactions.  
 Subsequently, a number of discoveries were made in association with specific 
HLA alleles and drug-induced SJS/TEN. The breakthrough discovery came from Chung 
et al. reporting the association of HLA-B*15:02 and CBZ-SJS/TEN in Taiwan Han 
Chinese. HLA-B*15:02 allele was found in 100% of CBZ-SJS/TEN cases and 3% of 
CBZ-tolerant controls and have a prevalent of 8.6% in the general population. It has the 
strongest strength of association reported thus far with an odds ratio of 2504 (95% CI 
126-49,522) (Chung et al., 2004). 
 Subsequent studies further confirmed the association in other Asian populations 
such as China, Thailand, Vietnam, Singapore, India, Malaysia and Indonesia (Chang et 
al., 2011; Chong et al., 2014; Herlyani et al., 2017; Locharernkul et al., 2008; Mehta et 
al., 2009; Nguyen et al., 2015; Then et al., 2011; Wu et al., 2010). The association of 
HLA-B*15:02 and CBZ-SJS/TEN was validated in Hong Kong Han Chinese and was 
also extended to include a weaker association to two other aromatic antiepileptic drugs, 
phenytoin and lamotrigine-induced SJS/TEN (Cheung et al., 2013). However, none of 
these association is as strong as that of CBZ-induced SJS/TEN. The association of HLA-
B*15:02 and PHT-SJS/TEN was also reported in Thai (Locharernkul et al., 2008; 
Tassaneeyakul et al., 2010). Two studies on west central and northern Indians from 
India demonstrate the association for HLA-B*15:02 and CBZ-SJS/TEN, where the 
allele is present in 75% of cases but none in tolerant controls (Aggarwal et al., 2014; 
Mehta et al., 2009). But in contrast, the northern Indian study did not found association 
for HLA-B*15:02 and PHT-SJS/TEN cases in which the allele is absent for both case 
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and tolerant controls, reflecting the low prevalence of the allele in the population (2-
6%) (Aggarwal et al., 2014). The association was also detected in Malaysian Malays, 
reporting the present of HLA-B*15:02 alleles in 75% of CBZ-SJS/TEN cases, compared 
to a general Malay population frequency of 15.7% (Chang et al., 2011). The most recent 
study from this region came from Vietnam and Indonesia. Nguyen et al. reported the 
presence of HLA-B*15:02 in 89.5% of CBZ-SCARs cases and 24% in tolerant controls, 
whereas it was noted that the prevalence of the HLA-B*15:02 in the population is 
considerably high, 13.5% (Nguyen et al., 2015). In Indonesia, HLA-B*15:02 allele was 
found in 57% of the CBZ-SJS/TEN cases and 26% of the tolerant controls (Herlyani et 
al., 2017). The association to HLA-B*15:02 was demonstrated to be phenotype-specific 
as HLA-B*15:02 does not shown association to MPE or DRESS induced by CBZ.  
 Conversely, the association was not found in Japanese and Koreans where the 
HLA-B*15:02 frequency in the population is very low (<1%) (Kaniwa et al., 2010; Kim 
et al., 2011; Ozeki et al., 2011). The risk of HLA-B*15:02 in predisposing to CBZ-
SJS/TEN was not detected in all studies on Caucasian populations either. A European 
study, by RegiSCAR group, tried to replicate the association of HLA-B*15:02 and 
CBZ-induced SJS/TEN in 12 European cases. They found four cases positive for HLA-
B*15:02, of which all four patients have Asian ancestry and the other patients that are 
negative for HLA-B*15:02 did not. In the other eight patients of European descent, no 
association to HLA-B*15:02 or to another HLA allele was detected (Lonjou et al., 
2006). The need to investigate genetic marker to SJS/TEN in Europeans prompted a 
genome wide association study of the largest sample size collected with enrollment of 
563 SJS/TEN cases. The strongest associated SNP was found located close to HLA-B 
locus. Still no other locus reached the genome-wide association threshold. This study 
lead to the conclusion that HLA-B*15:02 is not a marker for CBZ-induced SJS/TEN in 
Europeans population (Genin et al., 2011). This was also partly explained by the 
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ethnicity-specific variation in allele frequency of HLA-B*15:02. In European 
populations, the allele frequency of HLA-*15:02 is very low (<1%). This variation has 
also been correlated to the variation in incidence of CBZ-induced SJS/TEN.  
 In Japan and Korea, CBZ-SJS/TEN was associated with a different HLA-B 
allele, HLA-B*15:11 (Kaniwa et al., 2010; Kim et al., 2011). Interestingly, both HLA-
B*15:11 and HLA-B*15:02 alleles belongs to the same B75 serotype subfamily. A 
recent case study on CBZ-SJS/TEN in a HLA-B*15:02-negative Thai patient was 
shown to have another HLA-B75 members, HLA-B*15:21 (Jaruthamsophon et al., 
2017). The study further investigated the structural similarities between HLA-B*15:02 
and HLA-B*15:21 alleles in terms of CBZ binding and presentation to cytotoxic T-cells.   
 
2.6.2 HLA-A association to SJS/TEN-induced by antiepileptic drugs 
 Recently, HLA-A*31:01 allele was found in association with all CBZ-induced 
hypersensitivity reactions (including MPE, DRESS and SJS/TEN) in Japanese and 
Europeans (Amstutz et al., 2013; McCormack et al., 2011; Ozeki et al., 2011). 
However, this association has not been consistently replicated. HLA-A*31:01 was first 
reported associated to CBZ-maculopapular exanthema (MPE) in Han Chinese (Hung et 
al., 2006). Subsequent studies demonstrated that HLA-A*31:01 has a stronger 
association to CBZ-DRESS compared with a much weaker association to CBZ-
SJS/TEN in Han Chinese and Europeans (Genin et al., 2014). Due to inconsistent 
findings, association of HLA-A*31:01 with CBZ-SJS/TEN still requires further 
investigation in European and Asian populations. 
 Across these studies, it is evident that HLA association to AEDs-induced 
SJS/TEN is both phenotype- and ethnicity specific (Table 2.1). Numerous studies in 
different Asian populations point to the possibility that besides HLA-B*15:02 allele, 
other members of HLA-B75 family also predisposed risk to CBZ-SJS/TEN.  
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Table 2.1: Ethnicity and phenotype specific association between HLA allele and AEDs-
SCARs. 
 
AEDs HLA allele Population/ 
Ethnicity 
Phenotype Reference 
Carbamazepine  HLA-B*15:02 Han Chinese, 
Thai, Malays, 
Indians, 
Vietnamese, 
Indonesian 
SJS/TEN (Chang et al., 2011; 
Chung et al., 2004; 
Herlyani et al., 2017; 
Mehta et al., 2009; 
Nguyen et al., 2015; 
Tassaneeyakul et al., 
2010) 
       
  HLA-A*31:01 Caucasians, 
Japanese 
DRESS, 
MPE, 
SJS/TEN 
(McCormack et al., 
2011; Ozeki et al., 
2011) 
    Koreans DRESS, 
SJS/TEN 
(Kim et al., 2011) 
    Han Chinese DRESS, 
MPE 
(Genin et al., 2014;  
S. I. Hung et al., 2006) 
        
  HLA-B*15:11 Japanese, 
Koreans 
SJS/TEN (Kaniwa et al., 2010; 
Kim et al., 2011) 
Phenytoin HLA-B*15:02 Han Chinese, 
Thais 
SJS/TEN (Cheung et al., 2013; 
Locharernkul et al., 
2008) 
     
 HLA-B*15:13 Malays SJS/TEN (Chang et al., 2016) 
Lamotrigine HLA-B*15:02 Han Chinese SJS/TEN (Cheung et al., 2013; 
Zeng et al., 2015) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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2.7 Pathogenesis of carbamazepine-induced Stevens-Johnson syndrome/Toxic 
epidermal necrolysis 
 
2.7.1 SCARs Classification  
 The heterogeneous manifestation of SCARs feature is due to different regulatory 
cells that secrete cytokines. SCARs are classified under type IV hypersensitivity 
reactions according to the Gell and Coombs classification. Type IV reaction is a 
delayed-type of drug hypersensitivity mediated by T-cell with four subgroups according 
to the type of responsive T-cells and clinical presentation. IVa is mediated by type 1 T 
helper cells; IVb is mediated by T helper 2 cells, interleukins 4, 5 and 13 and eotaxin 
cytokines as found in DRESS; IVc is mediated by cytotoxic T-cells as found in SJS and 
TEN; and IVd is mediated by T cells and neutrophils through chemokine interleukin 8 
(IL8/CXCL8) and granulocyte-macrophage colony-stimulating factor. CBZ-induced 
SJS and TEN is classified under IVb drug hypersensitivity reactions, as it is mediated 
by drug-specific cytotoxic T-lymphocytes (Harr & French, 2010). 
 
2.7.2 Pathomechanism of SJS/TEN 
 The pathomechanism of SJS/TEN is not fully understood. Several studies on 
immunological mechanism of SJS/TEN have given valuable insight into the 
pathomechanism of SJS/TEN and in developing new methods for the treatment of 
SJS/TEN (Ko et al., 2011; Wei et al., 2012). The effect of wide spread keratinocytes 
apoptosis seen in SJS/TEN, which could not be explained by direct cell to cell contact 
of CTL alone, suggested the involvement of cytotoxic molecules. Analysis of blister 
fluid of SJS/TEN patients found various pro-inflammatory and anti-inflammatory 
cytokines. The massive T-cell meditated cell death observed in epidermal necrosis is 
attributed to three pathways, Fas-Fas ligand interaction, perforin-granzyme B pathway 
and granulysin-induced pathway. The most detrimental effect is by granulysin, which is 
responsible for the extensive keratinocyte necrosis without direct cell-to-cell contact. 
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This forms the basis of epidermal detachment seen in SJS/TEN (Duong et al., 2017; 
Harr & French, 2010). 
 In the initial phase, histological findings showed abundant CTL in blister fluid. 
The clonal expansion of CD8+ T-lymphocytes is an immune response to a major 
histocompatibility class-I restricted drug presentation. These CD8+ T-lymphocytes was 
found to express cutaneous lymphocyte-associated antigen (CLA). CLA is a ligand 
recognized by adhesion molecules E-and P selectin, which are expressed by inflamed 
skin cells (Nassif et al., 2004). It was demonstrated that T-cells from blister fluid 
exerted drug-specific cytotoxic activity towards B-lymphocyte and keratinocytes 
through secretion of granzyme B. Another study showed that the sera of SJS/TEN 
patients, containing elevated level of soluble FasL (sFasL), were able to induce 
keratinocytes apoptosis (Abe et al., 2003; Murata et al., 2008). Another molecule, 
granulysin, has also been detected in high level in serum and blister fluid of SJS/TEN 
patients. The activity of granulysin was demonstrated when injecting intradermally into 
mice, it showed feature of SJS/TEN (Abe et al., 2009). Other study supported this with 
in vitro assay showing that drug-specific cytotoxic T lymphocytes (CTL) expressed 
large amount of granulysin after triggered by CBZ leading to extensive keratinocytes 
apoptosis and eventually necrosis seen in the epidermal layer. One study suggested 
utilising granulysin as a biomarker in the prognosis of SJS/TEN (Chung et al., 2008).  
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2.7.3 HLA-drug interactions models 
2.7.3.1 Hapten concept 
 Previous studies have proposed several models to explain the phenomena of T 
cells recognition of small compounds like drugs and how T cell mediate the immune 
response. The model, first proposed, is hapten model. Small chemically reactive drug 
molecules formed covalent bonds with larger protein or peptide, eliciting a humoral 
immune response.  
 Pro-hapten, after metabolized or intracellular processing, became chemically 
active are able to elicit B and T cells response to the drug-modified peptide or protein. 
This is demonstrated in the case of penicillin hypersensitivity, where penicillin binds to 
serum albumin and undergo intracellular processing generating modified peptides that 
are able to elicit immune response (Figure 2.2) (Pichler et al., 2011).  
 
2.7.3.2 Altered repertoire model 
 Another hypothesis in pathogenesis of drug hypersensitivity is the altered 
peptide repertoire model. Drugs bind non-covalently to the MHC binding pocket 
altering the chemistry of the binding cleft and endogenous peptide repertoire. The new 
endogenous peptide presented leads to activation of cytotoxic T-cells. This model was 
conceptualized from the crystallographic structure of HLA-B*57:01 bound with 
Abacavir and peptide. Abacavir hypersensitivity syndrome has been found with strong 
association to HLA-B*57:01 allele. The peptide is presented by the HLA-B*57:01 to 
TCR while the drug is bound below the peptide and not in contact with the TCR-peptide 
interaction. Abacavir is found to bind noncovalent to HLA-B*57:01 molecule, causing 
changes in the peptides binding ability of HLA-B*57:01 molecule causing alteration in 
the repertoire of endogenous peptides presented to TCR (Figure 2.2) (Illing et al., 2012).  
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2.7.3.3 Pharmacologic interaction with immune receptors 
 The most relevant model to SJS/TEN induced by AEDs is the drug 
pharmacological interaction with immune receptors model: p-i concept. The drug or its 
metabolites binds directly to immune receptors such as HLA molecules or T-cell 
receptors (TCR) with noncovalent bonds without peptide ligand or intracellular 
processing. P-i reactions is attributed to the consequence of reactive T-cells. The 
component involved are the drug, HLA molecules on antigen presenting cells and T-cell 
receptor that subsequent leads to T cell stimulations. The p-i concept does not require 
metabolism of the drug or any processing. This is thought to be the case of CBZ-
induced SJS/TEN. CBZ binds directly to HLA-B*15:02 molecules (Figure 2.2) (Pichler 
et al., 2015).  
 Functional studies on HLA-B in the pathogenesisof SJS/TEN was carried out 
when it was observed that approximately up to 25% of CBZ-SJS/TEN patients of Asia 
ancestry do not have HLA-B*15:02 allele, hence it cannot be explained by HLA 
molecules alone. The studies investigated the role of HLA-B molecules binding to CBZ 
and activating cytotoxic T lymphocytes (CTL) mediated cell death. Ko et al. found T 
cells from CBZ-SJS/TEN patients that are also HLA-B*15:02 positive have TCR 
clonotype of Vβ-11-ISGSY. This clonotype was present in 17 from the 19 CBZ-
SJS/TEN patients while it was absent in all the CBZ-tolerant controls, suggesting 
requirement for cofactors that co-stimulate to develop a strong T cells stimulation (Ko 
et al., 2011). The mechanism of CBZ on T-cells response has also been compared to 
Abacavir. The CBZ-induced peptide repertoire shift is smaller than that observed in 
abacavir (Illing et al., 2012). The smaller shift also explained the more restricted TCR 
repertoire observed in reactive drug-specific T cells found in CBZ-SJS patients.  
 
	
30 
 
 
Figure 2.2: Models of interaction between human leukocyte antigen (HLA), small 
molecule (drug), peptide repertoire and T-cell receptor. (a) p.i. concept: The drug binds 
directly and noncovalently to HLA-peptide complex or to TCR on cell surface without 
intracellular antigen processing. The impact of drug on the peptide repertoire is less 
than the other two interaction models. (b) Hapten/pro-hapten concept: The drug or its 
reactive metabolite acts as hapten and binds covalently to endogenous peptides where 
the covalent modification to endogenous peptides generated neo-epitopes that are then 
presented on cell surface. These novel peptide-HLA–drug complexes are recognised as 
foreign by TCR. The immunogenic complexes generated are antigen-processing 
dependent.  (c) Altered repertoire model. The drug interacts with antigen-binding 
groove in HLA molecules, altering its conformation and thereby altering its binding to 
peptide ligand residues. This resulted in selection of peptides with novel HLA binding 
motif. The peptide-HLA (pHLA) complex is stable and require antigen processing 
pathway. Adapted from (Illing et al., 2016) 
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CHAPTER 3: METHODOLOGY 
 
3.1 Patient recruitment 
3.1.1 Cases  
 Patients with CBZ, PHT and LTG-induced SCARs were recruited by 
retrospective review of medical records from University Malaya Medical Centre 
(UMMC) (from 1991 to 2015) and Hospital Sultanah Bahiyah, Kedah (from May 2012 
to December 2015). This study was approved by UMMC medical ethics committee 
(No: 950.49) and Ministry of Health medical research and ethic committee (No.: nmrr-
13-1157-16170).  
 Drug causality of SJS/TEN was identified based on temporal relationship of 
drug intake and reactions onset. And assessed with Algorithm of drug causality for 
epidermal necrolysis (ALDEN). All cases were classified as probable or very probable 
with score of ≥6 (Sassolas et al., 2010). 
 Diagnosis of SJS and TEN was based on clinical presentation and confirmed by 
dermatologists according to criteria by Roujeau and Stern (1994). SJS, SJS/TEN and 
TEN were distinguished by extend of body surface area detachment (SJS <10%; 
SJS/TEN overlap 10-30%; TEN >30%) (Bastuji-Garin et al., 1993). In this study, 
different severity of SJS, SJS-TEN overlapped syndromes were grouped collectively as 
SJS/TEN. 
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3.1.2 Drug tolerant controls 
 Drug tolerant controls were patients receiving CBZ, PHT and LTG for at least 
three months without any adverse reactions. All tolerant controls were recruited from 
UMMC Neurology clinic. Tolerant control medical information and history of AEDs 
use were collected.  
 All participants in case and control groups were not of mixed ethnicity, as 
determined by the ethnicity of biological parents and grandparents. Written informed 
consent was obtained from all participants. Approximate 6ml of venous blood sample 
was obtained from each participant. In the event that blood sampling was not feasible, 
buccal swab was obtained. 
 
3.2 HLA-A and -B allele genotyping 
 Genomic DNA was extracted from blood samples using QiaAmp DNA kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. HLA-A and -B 
genotyping was performed with WAKFlow HLA typing kit (Wakunaga Pharmaceutical 
Co. Ltd, Japan) and analysed by Luminex 200 (Luminex, Austin, TX, USA) following 
the manufacturer’s instructions.  
 
3.3 Statistical Analysis 
 Comparisons of carrier frequencies of a particular HLA-A or -B allele between 
groups were performed with Fisher’s exact test. P-value is two-tailed. P-value < 0.05 
indicated statistical significance. Corrected Pc-value for multiple testing was performed 
with Bonferroni correction. The strength of association was calculated using 2x2 
contingency table, and presented as odds ratio, OR and 95% confidence interval, CI. 
Haldane's modification was used to counter for zero count cells in OR calculation. 
Sensitivity and specificity, positive and negative predictive values (PPV and NPV) were 
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also calculated from 2x2 contingency tables. Demographic characteristics of case and 
control in terms of age and sex were compared using non-parametric test, e.g. Mann-
Whitney test for continuous data and Chi-square test of independent for dichotomous 
data. Association analysis of combined samples was performed using Cochran–Mantel–
Haenszel 2×2×3 test (CMH) controlling for the differences among ethnic groups, and 
Breslow–Day test was used to evaluate the heterogeneity of OR among the ethnic 
groups. To study the effect of HLA-A and -B alleles on each other, logistic regression 
with the allele as a covariate under dominant model were performed. All statistical test 
was performed with PLINK (www.cog-genomics.org/plink2) (Purcell et al., 2007). 
Linkage disequilibrium analysis was performed with Haploview 
(www.broadinstitute.org/haploview/haploview) (Barrett et al., 2005). 
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CHAPTER 4: RESULTS 
 
4.1 Demographic characteristic of cases and tolerant controls 
 The characteristics of cases and tolerant controls are illustrated in Table 4.1. A 
total of 36 patients with AEDs-SJS/TEN, 3 AEDs-DRESS and 273 AEDs-tolerant 
controls were recruited in this study. Both cases and tolerant controls are categorised 
according to causal drugs and further sub-grouped by ethnicity. In total, there is 28 
CBZ-SJS/TEN (16 Malay, 6 Chinese and 6 Indian), 5 PHT-SJS (1 Malay, 2 Chinese 
and 2 Indians) and 3 LTG-SJS (1 Malay, 1 Chinese and 1 Indian) (Table 4.1). The three 
DRESS cases were consisted of 2 PHT-DRESS (1 Malay, 1 Chinese) and 1 CBZ-
DRESS (1 Malay).  For the AEDs tolerant controls subjects, they were grouped by the 
anti-epileptic drugs that they were tolerant to: 227 CBZ (57 Indian, 64 Malay, 106 
Chinese), 61 PHT (31 Malay, 30 Chinese) and 136 LTG (36 Indian, 44 Malay, 56 
Chinese). Hence the AEDs tolerant controls overlapped. This is to prevent sampling 
bias. There is no significant difference in age and sex between the SJS/TEN groups and 
the AEDs-tolerant controls groups. Demographic characteristics of DRESS cases were 
not compared to the AEDs-tolerant controls due to small sample size (Table 4.1). The 
following association analysis workflow for HLA-A and -B allele with AEDs-SCARs in 
the three ethnic groups is shown in Figure 4.1.  
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Table 4.1: Demographic characteristics of cases with AEDs-SCARs and AEDs-tolerant 
controls. 
 
    DRESS cases 
(n=3) 
SJS/TEN cases 
(n=36) 
AEDs-tolerant controls 
(n=273)  
P-value* 
Sex, n (%)      
  Female  2 (66.7) 18 (50.0) 132 (48.4)   
  Male 1 (33.3) 18 (50.0) 141 (51.6) 0.86 
Age (years), mean 
(range) 
53.7 (30-66) 38.1 (9-71) 37.5 (13-78) 0.99 
Race, n (%)      
  Malay  2 (66.7) 18 (50.0) 83 (30.4)   
  Chinese 1 (33.3) 9 (25.0) 119 (43.6)   
  Indian - 9 (25.0) 71 (26.0)   
Causal AED, n (%)      
  CBZ 1 (33.3) 28 (77.8) 227 (83.2)a   
  PHT 2 (66.7) 5 (13.9) 82 (30.0)a   
  LTG - 3 (8.3) 136 (49.8) a   
 
* Comparisons were preformed between SJS/TEN cases and AEDs-tolerant controls. 
DRESS cases were not compared due to limited case number.  
a AEDs-tolerant controls categorised into CBZ, PHT and LTG were overlapped (n/273).    
AEDs, Antiepileptic drugs; SJS, Steven-Johnson syndrome; TEN, toxic epidermal 
necrolysis; DRESS, Drug reaction with eosinophilia and systemic symptoms; CBZ, 
Carbamazepine; PHT, Phenytoin; LTG, Lamotrigine 
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Figure 4.1: Association analysis workflow of HLA-A and -B with AEDs-SCARs in 
Malays, Chinese and Indians. 
 
 
4.2 HLA-B association to SCARs-induced by antiepileptic drugs 
4.2.1 HLA-B alleles of AEDs-SJS/TEN cases 
 Specific HLA-B alleles that were present in AEDs-SJS/TEN cases and their 
allele frequencies were shown in Appendix A, B and C, categorised according to 
ethnicity.  
In the Malay CBZ-SJS/TEN cases, 16 HLA-B alleles were detected and HLA-
B*15:02 allele has the highest allele frequency (46.9%). Similarly, in Chinese CBZ-
SJS/TEN cases, 7 alleles were detected and HLA-B*15:02 has the highest allele 
frequency (33.3%). The same was found for Indian CBZ-SJS/TEN cases, in the 9 HLA-
B alleles detected, HLA-B*15:02 allele frequency was the highest (16.7%). However, in 
Indians, in addition to HLA-B*15:02, two other alleles, HLA-B*07:05 and HLA-
B*51:01, were also found at 16.7% in CBZ-SJS/TEN cases. Other than HLA-B*15:02, 
the other HLA-B alleles were not used in case-control comparison because of low 
HLA-A- and -B association to AEDs-SJS/TEN in Malays, Chinese and Indians
Sample size: AEDs-SJS/TEN, n=36; AEDs-tolerant controls, n=273
(AEDs-DRESS, n=3, were excluded due to limited samples)
HLA-B*15:02 and CBZ-SJS/TEN association detected in 
all three ethnic groups
Sample size: CBZ-SJS/TEN, n=28; CBZ-tolerant controls, 
n=227
HLA-A*31:01 and CBZ-SJS/TEN association 
detected in Indians 
Sample size: CBZ-SJS/TEN, n=6; CBZ-tolerant 
controls, n=57
Logistic regression analysis for HLA-A and B 
association to CBZ-SJS/TEN in Indians
Sample size: CBZ-SJS/TEN, n=6; CBZ-tolerant controls, 
n=57
HLA-B*15:02 and CBZ-SJS/TEN association 
in the combined ethnic group
Sample size: CBZ-SJS/TEN, n=28; CBZ-tolerant 
controls, n=227
Combined Analysis of HLA-B*15:02 and HLA-A*31:01
with CBZ-SJS/TEN in Indians
Sample size: CBZ-SJS/TEN, n=6; CBZ-tolerant controls, 
n=57
HLA-A- and -B genotyping
Sample size: AEDs-SCARs, n=39; AEDs-tolerant controls, n=273
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frequency (less than 10% allele frequency in either case or tolerant control group) 
(Appendix A, B and C). 
 
4.2.2 HLA-B*15:02 association to AEDs-SJS/TEN cases 
 Of the 28 CBZ-SJS/TEN cases and 227 CBZ-tolerant controls, association 
analysis was performed in the respective ethnic groups. In terms of carrier frequency, 
HLA-B*15:02 was detected in 87.5% of Malay, 66.7% of Chinese and 33.3% of Indian 
patients. Significant association was found in Malay (87.5% versus 12.5%; p = 2.00 x 
10-8; Odds ratio (OR) = 49.0; 95% confidence interval (CI) = 9.4 – 256.8), with a 
sensitivity of 87.5% and specificity of 87.5%, Chinese (66.7% versus 12.3%; p = 
0.0047; OR = 14.3; 95% CI = 2.4 – 86.0) with a sensitivity of 66.7% and specificity of 
87.8% and Indian (33.3% versus 3.5%; p = 0.042; OR = 13.8; 95% CI = 1.5-125.0) with 
a sensitivity of 33.3% and specificity of 96.5% (Table 4.2).  
 Of the 8 cases of PHT and LTG induced SJS, HLA-B*15:02 was detected in 
only 1 of the Malay PHT-SJS subject and none was found in LTG-SJS cases. No other 
HLA-B allele reach statistical significant in AEDs-SJS/TEN (Table 4.2). A post-hoc 
power analysis was performed for HLA-B*15:02 in PHT and LTG-SJS/TEN cases. 
Based on 10% of the controls carried the risk allele, the current sample size has 19% 
power for Malay cohort and 30% power for Chinese cohort. Both Malay and Chinese 
cohort requires a minimum of 7 cases to reach 80% power. While for Indian, based on 
3.5% of risk allele in controls the current sample size has 24% power. It requires 9 cases 
to reach 80% power.  
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Table 4.2: Association between HLA-B*15:02 and CBZ, PHT and LTG-SJS/TEN. 
 
  HLA-B*15:02 carrier frequency   
 N/total in group (%) OR (95% CI) P-value 
 
SJS/TEN cases 
(n=28) 
AED-tolerant controls 
(n=227)   
Carbamazepine       
Malay 14/16 (87.5) 8/64 (12.5) 49.0 (9.35 - 256.8) 2.00 x 10-8 
Chinese 4/6 (66.7) 13/106 (12.3) 14.3 (2.38 - 86.0) 0.0047 
Indian 2/6 (33.3) 2/57 (3.5) 13.8 (1.51 - 125.0) 0.042 
Phenytoin (n=5) (n=82)     
Malay 1/1 (100.0) 6/31 (19.4) 11.8 (0.43 - 323.8) 0.22 
Chinese 0/2 (0.0) 2/30 (6.7) 2.28 (0.08 - 61.8) 1 
Indian 0/2 (0.0) 1/21 (4.8) 2.73 (0.08 - 86.9) 1 
Lamotrigine (n=3) (n=136)     
Malay 0/1 (0.0) 6/44 (13.6) 1.97 (0.07-53.9) 1 
Chinese 0/1 (0.0) 8/56 (14.3) 1.90 (0.07-50.7) 1 
Indian 0/1 (0.0) 2/36 (5.6) 4.6 (0.15-144.7) 1 
 
P < 0.05 is considered significant 
AEDs, Antiepileptic drugs; SJS, Steven-Johnson syndrome; TEN, toxic epidermal 
necrolysis; CBZ, Carbamazepine; PHT, Phenytoin; LTG, Lamotrigine 
 
 
 
4.2.3 Association between HLA-B*15:02 and CBZ-SJS/TEN in the combined ethnic   
group 
 
 A combined association analysis of HLA-B*15:02 allele with CBZ-SJS/TEN in 
the three ethnic groups were performed by pooling into a stratified analysis using 
Cochran-Mantel-Haenszel test. In total, there is 28 CBZ-SJS/TEN cases and 227 CBZ 
tolerant controls. The overall association was found to be highly significant (PCMH = 
2.31 x 10-26, ORCMH = 26.6; 95% CI = 12.8 – 55.3). Breslow–Day test did not show 
significant evidence for odds ratio heterogeneity between ethnic groups (PBD = 0.26) 
(Table 4.3). 
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Table 4.3: Association between HLA-B*15:02 allele and CBZ-SJS/TEN stratified by 
ethnicity. 
 
Subgroup 
(Ethnicity) OR 95% CI ORCMH 95% CI PCMH PBD 
Malay 49.0 9.35 - 256.8 
   
 
Chinese 14.3 2.38 - 86.0 
   
 
Indian 13.8 1.51 - 125.0 
   
 
   26.6 12.8 - 55.3 2.31 x 10-26 0.26 
 
ORCMH: Cochran Mantel-Haenszel odds ratio; PCMH: p-value for Cochran Mantel-
Haenszel test 
PBD: Breslow-Day test p-value 
 
 
4.2.4 HLA-B allele and AEDs-DRESS cases 
 Of the 3 DRESS cases, 2 were induced by PHT (1 Malay, 1 Chinese) and 1 was 
induced by CBZ (1 Malay). One of 2 of the PHT-DRESS patient (Malay) was positive 
for HLA-B*15:02. The CBZ-DRESS patient was also positive for HLA-B*15:02. Due to 
limited sample, no association analysis was conducted for DRESS cases. Allele 
frequency of the other HLA-B alleles detected in CBZ-DRESS cases were shown in 
Appendix A and B.  
 
4.3 HLA-A association to SCARs-induced by antiepileptic drugs 
4.3.1 HLA-A alleles of AEDs-SJS/TEN cases 
 Specific HLA-A alleles that were present in AEDs-SJS/TEN cases and their 
allele frequencies were shown in Appendix D, E and F according to ethnicity. In Malay 
CBZ-SJS/TEN cases, a total of 15 HLA-A alleles were detected and HLA-A*11:01 has 
the highest allele frequency (21.9%). In Chinese CBZ-SJS/TEN cases, 9 HLA-A alleles 
were found and HLA-A*11:01 also presented with the highest allele frequency (25.0%). 
Whereas in Indian, 8 HLA-A alleles were detected and the highest frequency were found 
for HLA-A*31:01 (Appendix D, E and F). 
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4.3.2 HLA-A association to AEDs-SJS/TEN cases 
 HLA-A*31:01 was detected in 3 of the 6 Indian CBZ-SJS/TEN subjects with a 
significant association (carrier frequency: 50% versus 8.8%, p = 0.023; OR = 10.4; 95% 
CI = 1.6-65.8). HLA-A*31:01 was not present in both Malay and Chinese CBZ-
SJS/TEN cases, and the carrier frequency in Malay and Chinese CBZ-tolerant controls 
was detected at 6.3% and 2.8%, respectively (Table 4.4). HLA-A*02:06 was found with 
significant association in Indian CBZ-SJS/TEN subjects against CBZ tolerant controls 
(33.3% versus 1.8%, p = 0.022; OR = 28.0; 95% CI = 2.1-379.3) (Table 4.5).  
 HLA-A*11:01 detected with high frequency in Malay and Chinese CBZ-
SJS/TEN cases, were also found with similar frequency in the CBZ-tolerant controls of 
both ethnic groups (17.2% in Malay CBZ-tolerant controls and 23.6% in Chinese CBZ-
tolerant controls). Thus, comparisons were not conducted for HLA-A*11:01 as the allele 
frequency are similar for both case and control groups.  
 In PHT and LTG-induced SJS cases, no allele was statistically significant. HLA-
A*31:01 was not detected in either PHT or LTG induced SJS cases (Table 4.4). 
 
4.3.3 HLA-A allele in AEDs-DRESS cases 
 HLA-A*31:01 was not detected in all 3 cases of DRESS (2 PHT-DRESS and 1 
CBZ-DRESS). For the CBZ-DRESS case, HLA-A*24:02 was detected (Appendix D). 
Due to limited sample, no association analysis can be conducted for DRESS cases. 
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Table 4.4: Association of HLA-A*31:01 alleles and CBZ-SJS/TEN. 
 
Ethnicity HLA-A*31:01 carrier frequency 
OR (95% CI) P-value  N/total (%) 
 CBZ-SJS/TEN 
cases 
CBZ-Tolerant 
control 
 
    Malay 0/16 (0) 4/64 (6.3) 0.4 (0.02 - 7.96) 0.58 
Chinese 0/6 (0) 3/106 (2.8) 2.3 (0.1 - 48.9) 1.00 
Indian 3/6 (50.0) 5/57 (8.8) 10.4 (1.6 - 65.8) 0.02 
 
SJS, Steven-Johnson syndrome; TEN, toxic epidermal necrolysis; CBZ, Carbamazepine 
 
 
4.4 Logistic Regression analysis for HLA-A and HLA-B alleles associated with 
CBZ-SJS/TEN in Indians 
 
To assess whether the association of HLA-A alleles detected is independent of 
HLA-B*15:02 status in the Indian cohort, the subsequent association was performed 
conditioning for HLA-B*15:02. We found HLA-A*02:06 have a dependent effect on 
HLA-B*15:02 demonstrated by diminished association of HLA-A*02:06 after adjusting 
for HLA-B*15:02 (P = 0.112). The pairwise LD between HLA-A*02:06 and HLA-
B*15:02 is found to be moderate (D’ = 0.644; r2 = 0.306). In contrast, HLA-A*31:01 
demonstrated an independent effect from HLA-B*15:02 as the association persisted 
even after conditioning for HLA-B*15:02 (P = 0.019). This is also supported by the low 
LD observed between HLA-A*31:02 and B*15:02 (D’ = 0.141; r2 = 0.009) (Table 4.5). 
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Table 4.5: Conditional logistic regression for the association between HLA-A allele and 
CBZ-SJS/TEN in Indians. 
 
 
a The conditioning allele is treated as a covariate. 
SJS, Steven-Johnson syndrome; TEN, toxic epidermal necrolysis; CBZ, Carbamazepine 
 
 
4.5 Combined analysis of HLA-B*15:02 and HLA-A*31:01 with CBZ-SJS/TEN in 
Indians 
 
 In a combined analysis of both risk alleles, i.e. HLA-A*31:01 and HLA-B*15:02, 
three CBZ-SJS/TEN cases carried either risk allele and one patient carried both the risk 
alleles (4/6, 66.7%) whereas only 7 in 57 (12.3%) of CBZ-tolerant patients were carriers 
for either risk marker (P = 0.0068; OR 14.3; 95% CI 2.2-92.9), giving a sensitivity and 
specificity of 66.7% and 88.7%, respectively (Table 4.6).  
 
Table 4.6: Combined analysis of HLA-B*15:02 and HLA-A*31:01 in CBZ-SJS/TEN in 
Indians 
 
 
*carried HLA-A*31:01 or/and HLA-B*15:02 
*adjusted for multiple comparisons (n=3) 
 
 
Indians 
Carrier frequency, n/total (%) Odds Ratio 
(95% CI) 
P-value 
CBZ-SJS/TEN 
case 
CBZ-tolerant 
control 
HLA-A*02:06 2/6 (33.3) 1/57 (1.8) 28.0 (2.07 – 379.27) 0.012 
HLA-A*02:06 
a Conditioned for HLA-
B*15:02 
  12.3 (0.56 – 268.80) 0.112 
HLA-A*31:01 3/6 (50.0) 5/57 (8.8) 10.4 (1.64 – 65.80) 0.013 
HLA-A*31:01 
a Conditioned for HLA-
B*15:02 
  11.7 (1.49 – 91.11) 0.019 
  Combined carrier frequency* 
OR (95% CI) P-value PC-value  N/total (%) 
  CBZ-SJS/TEN case 
CBZ-Tolerant 
control 
Indian 4/6 (66.7) 7/57 (12.3) 14.3 (2.2 - 92.9) 0.0068 0.0204* 
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CHAPTER 5: DISCUSSION 
 
5.1 Overview: Population structure of Malaysia 
 The Malaysian population is unique where it is multi-ethnic and composed of 
three major ethnic groups, Malays (67.4 %), Han Chinese (24.6%) and Indians (7.3% ), 
in addition to other minority ethnic group (0.7%) (such as Ibans, Bidayuh, Kadazan and 
Dusun) (Department of Statistics, 2014-2016). Malaysia’s multi-ethnic population 
consisted of subpopulation from different genetic lineage contributing to a diverse and 
complex genetic makeup. The diverse ethnic composition of Malaysia population is 
illustrated by historical migratory events from neighbouring countries that shaped the 
population. Malaysia is situated along a major trading route between the East and West. 
In the 6th to 7th century, Melaka strait became an important maritime trading route and 
the sea traffic contributed immensely to establishing this region as a major entreport for 
international traders from India, China and Southeast Asia (Bellwood, 1993). This 
historical event shaped the interaction between Malay, India, Arab and China with the 
indigenous tribes (Orang Asli) in Malaysia. During the European colonisations (starting 
from 16th century), large groups of immigrant labours were brought in such as Chinese 
and Indian to work in tin mines and rubber plantations. The trading ports also attracted 
Malay subethnic groups from the nearby Indonesia archipelago for example from 
Sumatra, Java, Sulawesi and Kalimantan (Saw, 2007). Gene inflow from Chinese, 
Indians and Arabs traders with the contemporary Malays and Orang Asli tribes plus the 
European colonists have significant effect on the genepools (Norhalifah et al., 2016).  
 Population genetic structure studies revealed that among the three ethnic groups 
researched, Indians is more differentiated than Chinese and Malays, while the Chinese 
and Malays are closer (Hatin et al., 2011; Teo et al., 2009). The Malaysia Malay ethnic 
group are comprised of four major ancestral lineages (Austronesian, Proto-Malay, East 
Asian and South Asian). The predominant lineages are of Austronesian and Southeast 
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Asian aborigines in which Proto-Malays and aboriginal Taiwanese (Ami and Atayal) 
made up the largest component (Deng et al., 2015; Ko et al., 2014). The Chinese ethnic 
group comprised of Han Chinese descendants from southern provinces of China such as 
Guangdong and Fujian (Teo et al., 2009). Population structure studies show that 
Singaporean Chinese, which is of the same ethnic group as Malaysian Chinese, 
clustered together with Chinese sub-ethnic groups from Southeast Asia and Southern 
China (Teo et al., 2009). Indian ethnic group of Malaysia are mainly consisted of 
descendants from Telugas and Tamils from India south eastern region with a minority 
of Pathans and Sikhs from the northern part of India (Teo et al., 2009). Singaporean 
Indian, which is also of the same ethnic composition as Malaysian Indian, were shown 
to be closer to Central and South Asia population and European population. Substantial 
genetic variability was noted within the Indian cohort that was attributed it to sub-
ethnicities that existed in Indian population (Teo et al., 2009). The aspect of Indian 
population’s sub-ethnicities leading to genetic variability is further discussed in section 
5.2.  
 
5.2 HLA-B association to CBZ-induced SJS/TEN 
 As the association of HLA-B allele and CBZ-SJS/TEN has not been researched 
in the Indian ethnic group of Malaysia, this aspect is of much interest. So far, there were 
two published studies on association of HLA-B*15:02 and CBZ-SJS/TEN in Indians. 
One study sampled from Modasa, a city in Northwest India in the state of Gujarat 
(Mehta et al., 2009) while the second study were from Chandigarh, a city in the North 
India (Aggarwal et al., 2014). However, in India, the allele frequency of HLA-B*15:02 
is not homogeneously distributed (Gonzalez-Galarza et al., 2015). Indian populations 
are genetically diverse due to different waves of immigration resulting in subdivided 
castes and tribes which is further subdivided by geography, language and religion 
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forming a non-panmictic population, in which the mating within the breeding 
population is not random. This is supported by evidence that groups in India inherited 
different proportions of ancestry from Ancestral North Indians and Ancestral Southern 
Indians, two genetically diverse ancient populations (Reich et al., 2009). The most 
recent immigration is Indo-European speakers that entered India primarily from the 
northwest establishing the Hindu caste system and after initial admixture, the 
indigenous Dravidian-speakers were displaced and migrated southward. Population 
structure studies showed admixture of Central and West Asians population with 
Northern Indian population as evidenced by lower genetic differentiation between 
Central Asian and Northern Indian population than with Southern Indian populations. 
Indian population can be broadly classified into Northern Aryans and Southern 
Dravidians (Basu et al., 2003). 
 HLA-B*15:02 allele frequency in Indian population ranges from 0-6% 
depending on region (0% in west coast Parsi, 1.6% in northern Indian, to 4% in west 
Bhil, and 6% in Pawra in Khandesh region) (Gonzalez-Galarza et al., 2015), but not 
available for southern India. This study fills a gap in the prevalence of HLA-B*15:02 
among Malaysia Indian ethnic groups, which are predominantly Southern Indian. 
 Earlier in the course of this study, in the Indian cohort of 5 CBZ-SJS/TEN cases 
and 52 CBZ-tolerant controls, I reported a significant association between HLA-
B*15:02 and CBZ-SJS/TEN (40% vs. 3.8%, OR 16.7, 95% CI 1.70–163.0, p = 0.0349), 
despite a low carrier frequency of HLA-B*15:02 in Indians (3.8%) (Khor et al., 2014). It 
is also the first reported association between HLA-B*15:02 and CBZ-SJS/TEN in 
cohort of predominantly Southern Indians. At that time of the study, meta-analysis was 
carried out between my Indian cohort with Mehta et al. from Northwest India (Mehta et 
al., 2009) as it was the only published study on CBZ-SJS/TEN in Indians. The 
combined studies shown strong association (OR=38.54; 95% CI=6.83–217.34, p < 1.03 
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x 10-4) confirming HLA-B*15:02 as a valid pharmacogenetic marker for CBZ-SJS/TEN 
in the Indian population. At the end of this study, with the increase in sample size 
(addition of 1 CBZ-SJS/TEN and 5 CBZ-tolerant controls in Indians) I further confirm 
the association between HLA-B*15:02 and CBZ-SJS/TEN in Indians. 
 Furthermore, this study replicated the association between HLA-B*15:02 and 
CBZ-SJS/TEN in Malay and Chinese. The association was confirmed between HLA-
B*15:02 and CBZ-SJS/TEN separately in each ethnic group as well as in the combined 
analysis of all the three ethnic groups, whereby Breslow-Day test demonstrated non-
significant heterogeneity of OR between the ethnic groups. The reason the association 
was analysed separately according to ethnicity is to avoid population stratification. 
Allele frequencies are known to vary among different ethnic population due to different 
genetic background, ancestral migration patterns, social history or mating practices. 
This is even more striking for HLA alleles whose frequencies differ greatly by ethnicity 
(Gonzalez-Galarza et al., 2015). These frequency discrepancies may cause confounding 
issues if not controlled for. One way to reduce stratification is to match control to case 
by sampling the control from the same source population from which cases are sampled, 
hence keeping allelic differences to a minimum. Another approach is structure 
assessment by subdividing into homogenous population (ethnicity), hence the 
subgroups are matched appropriately. The association test is performed in each matched 
subgroup before each subgroup is statistically combined to obtain the total test for 
disease association. Thus, the analysis for association between HLA-B*15:02 and CBZ-
SJS/TEN in the three ethnic groups were conducted in this manner. A post-hoc power 
analysis was performed for HLA-B*15:02 in CBZ-SJS/TEN cases. Based on 10% of the 
controls carried the risk allele (HLA-B*15:02) and a sample of 16 cases, a 4:1 ratio of 
controls to cases have 99% power for Malay, whereas in the Chinese cohort based on 
the same frequency of 10% of risk allele in controls in a sample of 6 cases, a 17:1 ratio 
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of controls to cases have 86% power. As for HLA-B*15:02 in Indian CBZ-SJS/TEN 
cases, based on 3.5% of the controls carried the HLA-B*15:02 allele and a sample of 6 
cases, a 9:1 ratio of controls to cases have 61% power. Therefore, this study has more 
than 80% power to detect an effect size in the Malay and Chinese cohort. However, in 
the Indian cohort, the power did not reach 80% due to a lower HLA-B*15:02 frequency 
in controls.   
 Nonetheless, this present study investigated by far the largest number of AEDs-
SCARs cases and AEDs tolerant controls representing the three major ethnic groups in 
Malaysia. Other than HLA-B*15:02, no other HLA-B allele was significantly associated 
with CBZ-SJS/TEN in this study (Gonzalez-Galarza et al., 2015). 
 
5.3 HLA-A association to CBZ-induced SJS/TEN 
 A significant association was detected between HLA-A*31:01 and CBZ-
SJS/TEN in Indian ethnic group, which is made up of southern Indians. In the Indian 
cohort, HLA-A*31:01 test has a 50% sensitivity and 91.2% specificity for detecting 
CBZ-SJS/TEN. The association between HLA-A*31:01 and CBZ-induced 
hypersensitivity reactions was previously reported in Europeans, Japanese and Hans 
Chinese populations. HLA-A*31:01 had been associated with different CBZ-induced 
hypersensitivity phenotypes ranging from mild rash to SJS/TEN and DRESS in a few 
populations but the association to CBZ-SJS/TEN was comparatively much weaker 
(Amstutz et al., 2014; Genin et al., 2014). The different association detected may also 
be influenced by background allele of the population, as seen in the prevalence of HLA-
B*15:02, where carrier frequency is higher among the south Asian population (12-
15.7% in Malay, 14.5% in Han Chinese, 13.5% in Vietnamese, 18% in Thai), in 
contrast, in Indian it is at 3.5% and it is much lower in European (< 1%), Japanese (1-
2%), and Korean (1-2%) populations. Whereas HLA-A*31:01 has a more average 
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background carrier frequency in these populations (2.8% in Han Chinese, 7.1-12% in 
Japanese, 5.4% in Koreans and 2-4.1% in Caucasian) and the allele frequency of HLA-
A*31:01 (ranges at 1.9-18.9%) observed in Indian is also higher compared to HLA-
B*15:02 frequency (2-6%) (Gonzalez-Galarza et al., 2015). 
 However, HLA-A*31:01 was not detected in any of the 3 AEDs-DRESS 
patients, even though several studies have consistently demonstrated that HLA-A*31:01 
is more strongly associated with CBZ-DRESS than with CBZ-SJS/TEN. Similarly, in 
this Malay and Chinese CBZ-SJS/TEN cohorts, the association between HLA-A*31:01 
and CBZ-SJS/TEN was not detected and the carrier frequency was found at 6.3% and 
2.8% in Malay and Chinese tolerant controls, respectively. The reported association of 
HLA-A*31:01 and CBZ-induced hypersensitivity are more diverse and not exclusive to 
one phenotype of drug hypersensitivity reactions unlike the association of HLA-
B*15:02 with CBZ-SJS/TEN. The mechanism behind HLA-A*31:01 association to 
various CBZ-hypersensitivity phenotypes is not known. As most of the research on 
CBZ-hypersensitivity reactions were on HLA-B*15:02 interaction with CBZ, peptides 
and TCR (this topic is discussed in section 5.7.2), studies investigating HLA-A*31:01 
interaction in CBZ-hypersensitivity is very limited. So far there is only one case study 
that show activation of CBZ-specific CD8+ T-cells restricted by HLA-A*31:01 and 
CBZ-specific CD4+ T cells restricted by HLA-DRB1*04:04 (Lichtenfels et al., 2014). 
Illing et al. suggested that HLA-A*31:01, sharing 2 of the 3 key amino acid residues 
(Ile95 and Leu156 but not Asn63) involved in CBZ binding to HLA-B*15:02, may play 
a role in the interaction with CBZ (Illing et al., 2013). However, it is still unclear why 
HLA-B*15:02 is specific to CBZ-SJS/TEN whereas HLA-A*31:01 predispose to 
various CBZ-hypersensitivity. The molecular mechanism of HLA-A*31:01 in CBZ-
hypersensitivity and its interaction with TCR will required further study. 
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 But given previous findings, our data increased the potential clinical utility of 
HLA-A*31:01 genetic screening test in predicting CBZ-SJS/TEN in Southern Indians. 
A post-hoc power analysis for HLA-A*31:01 in Indian CBZ-SJS/TEN cases was 
performed based on a frequency of 8.8% of risk allele in controls and a sample of 6 
cases, a 9:1 ratio of controls to cases have 66% power. Therefore, combined analysis of 
both HLA-A*31:01 and HLA-B*15:02 risk variants improved the predictive power in 
identifying patient with increased risk for CBZ-SJS/TEN in Indian population where 
HLA-B*15:02 frequency is lower and not homogeneous. Although my study is limited 
by small CBZ-SJS/TEN cases in Indians, and further confirmation of this association is 
needed, the findings support genetic testing for both	HLA-B*15:02	and	HLA-A*31:01 in 
Indian patients prior to CBZ treatment. 
 
5.4 HLA association to PHT and LTG-SJS/TEN 
 No HLA-A and -B allele reach statistical significant in PHT and LTG-SJS/TEN 
cases. Post-hoc power analysis shown the current sample size lacked power to detect an 
effect size. A minimum of 9 cases for Indians and 7 for Malay and Chinese is required 
to reach 80% power. As evidenced from other studies, the strength of association 
between HLA-B*15:02 in PHT and LTG-SJS/TEN was weaker compared to CBZ-
SJS/TEN and it was not detected in other population besides Han Chinese. Therefore, to 
detect an association, a bigger sample size for each ethnic group will be necessary. 
 PHT, an aromatic antiepileptic drug, is also a neutral tricyclic ring compound 
similar to carbamazepine and lamotrigine. These three drugs have similar mechanism 
and pharmacological action demonstrated by sharing of a common pharmacophore. 
They act on voltage-gated sodium channels and interact with the same amino acid 
residues in the inner pore of neuronal Na+ channel. They have similar affinity to Na+ 
channel which is voltage-dependence with low affinity at resting state and high affinity 
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for open-inactivated states (Lipkind & Fozzard, 2010). However, there is no study on 
PHT and LTG interaction with HLA-B*15:02 molecule. Nonetheless, HLA-B*15:02 
association to PHT and LTG-SJS/TEN has been reported in Han Chinese and Thai 
(Cheung et al., 2013; Locharernkul et al., 2008). PHT-SCARs were also reported in 
association with HLA-B*15:13 in Malays (Chang et al., 2016). In my cohort, there is 
two CBZ-SJS/TEN patients carrying HLA-B*15:13 allele, but none in PHT-SJS/TEN 
cases. This is due to small sample size and ethnic-specific genetic background (5 PHT-
SJS/TEN cases, of which only one is of Malay ethnicity). HLA-B*15:13 has high 
prevalent in Malaysian Malays and Indonesian (6.9-12.5% and 11-13.3% respectively), 
but low in other South Asian population (0.1-0.3% in Han Chinese, 1.8% in Thai).  
 Lamotrigine (LTG), a tricyclic aromatic antiepileptic drug similar to CBZ and 
PHT, is a one of the common high risk drug in SJS/TEN. Risk of SJS/TEN is reported 
at 2.5 per 10,000 new users of LTG (Mockenhaupt et al., 2005). LTG-SJS/TEN has 
been reported in association with HLA-B*15:02 in Han Chinese. However, due to small 
sample size and lower incidence of LTG-SJS/TEN, the strength of association between 
HLA-B*15:02 and LTG-SJS/TEN (OR 4.98) was found consistently weaker than to that 
of CBZ-SJS/TEN (OR 80.70-113.39) (Grover & Kukreti, 2014; Yip et al., 2012; Zeng 
et al., 2015). In a LTG-SJS/TEN study of European ancestry, HLA-B*15:02 was not 
detected and no HLA allele reached statistical significant, but the author implicated 
involvement of other HLA alleles (HLA-B*58:01, A*68:01, Cw*07:18, DQB1*06:09, 
and DRB1*13:01) (Kazeem et al., 2009). In Koreans, another allele, HLA-B*44:03, was 
detected in association to LTG-SJS/TEN (Park et al., 2016). Similarly, HLA-B*15:02 
was not detected in my LTG-SJS/TEN cases (of the 3 LTG-SJS/TEN cases, it is 
consisted of 1 Malay, 1 Chinese and 1 Indian). This is due to limited sample size and 
ethnicity-specific genetic background.  
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 HLA-A*24:02 was recently reported to be a shared predisposing risk factor for 
SJS/TEN induced by aromatic antiepileptic drugs, CBZ, PHT and LTG in southern Han 
Chinese, in addition to confirming association of HLA-B*15:02 in CBZ-SJS/TEN. 
Interestingly, HLA-A*24:02 was found in CBZ-SJS/TEN cases that were negative for 
HLA-B*15:02, suggesting HLA-A*24:02 is an independent risk factor. In my cohort, 
two HLA-B*15:02-negative Chinese AEDs-SJS/TEN patients (1 CBZ-SJS/TEN and 1 
LTG-SJS/TEN) has HLA-A*24:02. The authors hypothesized that both HLA-B*15:02 
and HLA-A*24:02 have an accumulative effect and contributed to AEDs-SJS/TEN (Shi 
et al., 2017).  
 
5.5 Cross-Reactivity in SCARs 
 Aromatic antiepileptic drugs (AEDs), in particular carbamazepine, phenytoin, 
phenobarbital, and lamotrigine, are some of the common high rick medications 
associated with severe cutaneous adverse reactions. Cross-reactivity between these 
aromatic antiepileptic drugs is not uncommon (Hirsch et al., 2008). A large-scale study 
investigating risk predictors of AEDs-induced rash found that one of the strongest 
predictors is a history of rash with another AED (Arif et al., 2007). This finding is 
supported by another study showing a significant association between carbamazepine-, 
phenytoin-, and oxcarbazepine–induced hypersensitivity skin reactions with a previous 
history of AEDs-induced rash (Alvestad et al., 2008). In vitro lymphocyte toxicity assay 
study found 80% of the cases that had hypersensitivity to one drug showed cross-
reactivity to another aromatic antiepileptic drug (Shear & Spielberg, 1988). Study on 
AEDs-SJS/TEN have found HLA-B*15:02 associated to CBZ-SJS/TEN and the 
association was shared by PHT and LTG-SJS/TEN, albeit weaker. 
 Here, I describe a patient in my cohort with SJS induced by LTG after a history 
of CBZ-induced SJS. The patient is a 63-year-old Indian woman with a diagnosis of 
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right-sided trigeminal neuralgia diagnosed since 2002. Carbamazepine was prescribed 
and resulted in complete pain relief. Fourteen days later, the patient developed a 
generalized rash on the trunk and limbs and was diagnosed with carbamazepine-induced 
SJS (ALDEN score 6). The second hypersensitivity event occur ten years later. The 
patient was started on LTG due to uncontrolled pain. On day 20, while on LTG 100 mg 
a day, the patient developed a second episode of SJS (ALDEN score 8). HLA-A and -B 
allele genotyping detected HLA-A*02:11 and A*24:17 and HLA-B*40:06 and B*51:06. 
These alleles have not been reported in association with AEDs-induced SJS/ TEN (Khor 
et al., 2016). 
 Negative results for known HLA-alleles associated with AEDs-induced severe 
cutaneous adverse drug reactions, such as in this case, does not predict against cross-
reactivity. Although these reactions are unpredictable, identification of predisposing risk 
factors prior to drug selection can reduce the probability of a hypersensitivity reaction. 
Patients with a history of severe cutaneous adverse reactions to aromatic AEDs such as 
carbamazepine, phenobarbital, phenytoin, and lamotrigine are strongly recommended to 
be managed with newer AEDs that has a lower risk of severe cutaneous adverse 
reactions. 
 This case show that in patient with history of AEDs-SJS/TEN, the adverse 
reaction can recur with another aromatic AED. Therefore, precautions should be taken 
to avoid these aromatic AEDs in patients with previous history of AED-SJS/TEN. 
Although HLA-genotyping helps to predict AEDs-SJS/TEN reactions, negative results 
for known HLA-alleles (HLA-B*15:02 and HLA-A*31:01) does not predict absence of 
risk to SJS/TEN especially patient has a previous history of AED-induced severe 
cutaneous adverse drug reactions. In addition, for those with positive HLA-B*15:02, 
although the recommendation is to avoid carbamazepine, caution should also be taken 
when considering another aromatic AEDs.   
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5.6 HLA Screening: Cost-effectiveness and AEDs dosing guideline 
5.6.1 HLA-B*15:02 screening 
 In health care, adverse reaction to drugs is one of the main cause of morbidity 
and mortality. Drug-related morbidity and mortality costed an estimated 136 billion 
USD annually in US, which is higher than compared to common diseases such as 
diabetes or cardiovascular disease (Johnson & Bootman, 1995). The United States Food 
and Drug Administration (FDA) changed the CBZ label to include warning and strongly 
recommend but did not mandate HLA-B*15:02 screening prior to starting CBZ in 
Asians in December 2007 (https://www.fda.gov/drugs/drugsafety/postmarketdrugsafety 
informationforpatientsandproviders/ucm107834.htm) (Ferrell & McLeod, 2008). A 
prospective study in Taiwan demonstrated that HLA-B*15:02 screening prior to CBZ 
treatment reduced incidence of SJS/TEN from 10 expected SJS/TEN cases to 0 (P. 
Chen et al., 2011). Subsequently, Taiwan implemented HLA-B*15:02 screening 
mandatory prior to starting CBZ treatment. This was follow by Hong Kong. Singapore 
in April 2013 recommended HLA-B*15:02 screening as standard of care. In Malaysia, 
the screening patient for HLA-B*15:02 is strongly recommended as standard of care as 
well. Prevention measurement of AEDs-induced SJS/TEN in Southeast Asia is mostly 
involving limiting exposure of susceptible patient that are carrier of HLA-B*15:02 by 
prescribing alternative medication. HLA-B*15:02 screening prior to starting CBZ 
treatment is strongly advocated. The cost-effectiveness and usefulness of HLA-B*15:02 
screening prior to CBZ treatment has been demonstrated to be cost-effective in 
population where prevalence of HLA-B*15:02 is high by several studies from Taiwan, 
Hong Kong, Thailand and Singapore (Chen et al., 2014b; Dong et al., 2012; 
Rattanavipapong et al., 2013).  
 
 
	
54 
5.6.2 HLA-A*31:01 screening 
 HLA-A*31:01 has been shown to associated with CBZ-hypersensitivity 
reactions in several populations including Han Chinese, European and Japanese, but 
HLA-A*31:01 screening has not been implemented as of now. It was included in CBZ 
drug label as information only. However, unlike HLA-B*15:02 whose prevalent is 
mostly restricted to Southeast Asia population, HLA-A*31:01 is more widely distributed 
in many different population (Gonzalez-Galarza et al., 2015). Many studies are in favor 
of HLA-A*31:01 screening as it is more useful in populations where HLA-B*15:02 is 
rare. 
 No prospective study on HLA-A*31:01 was published at the moment. There 
were 3 systematic review examining the association of HLA-A*31:01 and CBZ-
hypersensitivity reaction in a few ethnic groups (Caucasian, Japanese, Koreans and Han 
Chinese). Odds ratio (OR) ranging from 3.9 to 14 was reported with the highest OR 
found for association to CBZ-DRESS in Caucasian. The number needed to test (NNT) 
to prevent one case of CBZ-hypersensitivity reactions was reported with NNT of 47 for 
Caucasian and 67 for Japanese based on an estimated incidence of CBZ-hypersensitivity 
reaction of 10% and 2.9% respectively (Amstutz et al., 2014; Genin et al., 2014; Grover 
& Kukreti, 2014). In Han Chinese, the NNT to prevent one case of CBZ-DRESS was 
5000 as the incidence of CBZ-DRESS was estimated at 0.05%. One of the studies 
demonstrated the combined HLA-A*31:01 and HLA-B*15:02 test in Han Chinese 
population has NNT of 455 (Genin et al., 2014). 
 A cost-effectiveness study on HLA-A*31:01 screening conducted in the United 
Kingdom showed that routine testing is cost-effective with a predicted reduction of 
estimated 780 to 700 CBZ-hypersensitivity cases per 10,000 patient (Plumpton et al., 
2015). 
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5.6.3 HLA genotyping and AEDs dosing guideline 
 Guideline on the use of pharmacogenetic test such as HLA-B*15:02 in CBZ 
dosing has been published by Clinical Pharmacogenetics Implementation Consortium 
(CPIC), an international consortium aiming to facilitate the use of pharmacogenetic test 
in clinical practice. The consortium addresses the barrier faced in implementing 
pharmacogenetic testing in clinical practice due to difficulty of translating the test 
results into an actionable decision in drug prescribing for clinician. CPIC curates and 
systematically grade the published evidence and clinical recommendations to establish 
their guidelines by categorising dosing recommendations into strong, moderate and 
optional (Table 5.1). In the case of HLA-B genotyping test for CBZ dosing, the 
consortium follows FDA recommendation that “patients with ancestry in at-risk 
populations should be screened for the presence of HLA-B*15:02 allele prior to starting 
carbamazepine” (https://www.fda.gov/drugs/drugsafety/postmarketdrugsafety 
informationforpatientsandproviders/ucm107834.htm) (Ferrell & McLeod, 2008). In 
addition, CPIC further stated the highest risk patients are from Han Chinese descent, 
followed by Vietnam, Cambodia, the Reunion Islands, Thailand, India (specifically 
Hindus), Malaysia, and Hong Kong. The other populations not stated are categorized as 
low frequency. But they emphasize that patient may be unaware of presence of distant 
Asian ancestry in their family. Hence, recommended strongly that patient should be 
tested for HLA-B*15:02 regardless of ancestry or age. If the test is positive, alternative 
medication should be used. The consortium justified the denial of CBZ to HLA-
B*15:02-positive patient although they acknowledge that the number needed to test 
(NNT) to prevent one case of CBZ-SJS/TEN in Asian for HLA-B*15:02 test is 461(Yip 
et al., 2012), which is quite a large number of HLA-B*15:02-positive patients that 
would not develop CBZ-SJS/TEN. However, they argued the benefit outweighed the 
risk considering the severity and long-term sequelae of SJS/TEN. The consortium also 
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recommends that consideration should be taken for other AEDs with aromatic ring that 
are similar structurally and therapeutically to CBZ, such as phenytoin, lamotrigine, 
oxcarbazepine and eslicarbazepine acetate, for choosing alternative to CBZ (Leckband 
et al., 2013). In agreement with this, current practice strongly discourage choosing 
aromatic AEDs with similar structure that are also associated with risk to SJS/TEN as 
alternative to CBZ. Instead, newer AEDs with no risk of SJS such as sodium valproate 
or levetiracetam are recommended as CBZ alternative. CPIC guidelines are updated 
periodically and available on CPIC website (cpicpgx.org) and PharmGKB website 
(http://www.pharmgkb.org) 
 Recent emerging evidences on HLA-A*31:01 association to multiple CBZ-
hypersensitivity reactions (including SJS/TEN, MPE and DRESS) detected in a large 
number of populations (such as Japanese, Caucasian, Han Chinese and South Korean) 
has prompted update to screening recommendations. A systematic review reported that 
NNT to prevent one case of CBZ-hypersensitivity reactions for HLA-*31:01 screening 
(67 for Japanese and 47 for Caucasian) is lower compared to HLA-B*15:02. But the 
author noted that if NNT is specifically for preventing SJS/TEN only, HLA-B*15:02 
screening is more favorable (Leckband et al., 2013; Yip et al., 2012). Another study 
strongly recommended HLA-B*15:02 testing while moderately recommended HLA-
A*31:01 testing for all CBZ-naive patient prior to CBZ treatment explaining the 
reduced recommendation of HLA-A*31:01 is because of smaller number of studies and 
citing uncertainty in the sensitivity and PPV due to lack of prospective study on the 
HLA-A*31:01 in reducing CBZ-hypersensitivity reactions (Amstutz et al., 2014). 
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Table 5.1: CPIC Guidelines - Classification and definition of the strength of therapeutic 
recommendations.* 
 
Classification of 
recommendations 
CPIC definition  
Strong The evidence is high quality and the desirable 
effects clearly outweigh the undesirable effects. 
Moderate There is a close or uncertain balance as to whether 
the evidence is high quality and the desirable 
clearly outweigh the undesirable effects. 
Optional The desirable effects are closely balanced with 
undesirable effects and there is room for 
differences of opinion as to the need for the 
recommended course of action. 
 
 
*Adapted from Clinical Pharmacogenetics Implementation Consortium Guidelines for 
HLA-B Genotype and Carbamazepine Dosing 
(www.pharmgkb.org/guideline/PA166105008) (Leckband et al., 2013) 
 
 
5.7 Other risk factors implicated in AEDs-SJS/TEN 
5.7.1 T-cell receptor  
 Meta-analyses of published studies on the association between HLA-B*15:02 
and CBZ-SJS/TEN showed that there are approximately 25% of CBZ-SJS/TEN cases 
negative for HLA-B*15:02 (Genin et al., 2014; Grover & Kukreti, 2014; Yip et al., 
2012). It seems HLA-B*15:02 is important but not necessary for CBZ-SJS/TEN. 
Functional study on the T-cell receptors (TCR) repertoire in recognition of CBZ 
presented by HLA molecules in the context of CBZ-SJS/TEN disease revealed other 
key risk factors besides HLA-B*15:02. Specific TCR clonotype, VB-11-ISGSY, was 
present in 84% of SJS/TEN patients while absence in all of the tolerant controls, 
revealing that TCR usage in CBZ-SJS/TEN patients is restricted (Ko et al., 2011). Illing 
et al. observed the shift in peptide repertoire caused by CBZ binding to HLA-B*15:02 
molecule is smaller and it corroborates with restricted TCR usage observed in CBZ-
SJS/TEN patients (Illing et al., 2012).  
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5.7.2. Antigen binding site in HLA-B molecule 
 Another study investigated the presentation of CBZ by HLA molecules 
demonstrated that HLA-B*15:02-β2-microglobulin-pepetide complex has high affinity 
for chemical with 5-carboxamide on tricyclic ring such as CBZ. They found 3 key 
residues (Asn63, Lle95 and Leu 156) in the peptide binding groove of HLA-B*15:02 
that are necessary for CBZ presentation which lead to CTL activation (Wei et al., 2012). 
The key residue, Asn63, are also shared by other alleles of the HLA-B75 family 
explained why alleles in this family are able to present CBZ while other family (HLA-
B62 and HLA-B72) could not. Mutagenesis of these three sites abolished CBZ binding 
to HLA-B*15:02 recombinant protein and CTL recognition of CBZ (Wei et al., 2012). 
Other allele of HLA-B75 family that was reported with association to CBZ-SJS/TEN is 
HLA-B*15:11 in Japanese (Kaniwa et al., 2010) and HLA-B*15:21 in a pooled Asian 
cohort (Jaruthamsophon et al., 2017). Another HLA-B75 family allele, HLA-B*15:08, 
was not statistically associated with CBZ-SJS/TEN but it was detected in HLA-
B*15:02-negative CBZ-SJS/TEN patients of Indian ethnicity (Mehta et al., 2009). 
Consistent with my study’s observation, one of the Indian CBZ-SJS/TEN patients is 
positive for HLA-B*15:08. It was not detected in CBZ-SJS/TEN cases of Chinese and 
Malay. HLA-B*15:08 is found more prevalent in Indian than Chinese and is absence in 
Malay. Whereas for HLA-B*15:21 frequency, it is higher in Malays than in Chinese and 
Indians (Gonzalez-Galarza et al., 2015). But it was not detected in any of the cases in 
this study.  
 Studies on the antigen-binding groove of HLA-B75 family suggested that HLA-
B75 family members have similar conformation that enable the binding and 
presentation of CBZ. Wei et al. (2012) supported this by showing antigen presenting 
cell transfected with B75 family members was able to induce in vitro CBZ-specific CTL 
cytotoxicity (Wei et al., 2012). In-silico molecular conformation modelling show the 
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key binding site for CBZ is Arg62 in HLA-B*15:02 molecule while Asn63 attributes to 
molecular recognition. In fact, the structure of antigen binding groove is not key 
determinant of CBZ binding, the selectivity is attributed to amino acid side chain 
(Jaruthamsophon et al., 2017). The strongest binding site was found on the side chain of 
Arg62 which form a hydrogen bond with ketone group of the 5-carboxamide of CBZ 
(Wei et al., 2012). It has been proven that CBZ binds directly and noncovalently to 
HLA-B*15:02 molecules and lead to an altered peptide repertoire capable of eliciting T-
cells response. Taken together the findings, it is apparent that HLA molecules is 
susceptible to antigen selection modulation by drugs that in turn elicits altered T-cell 
immunity. Studies on pathogenesis of HLA-A*31:01 and CBZ-hypersensitivity is more 
limited. So far, no binding sites of CBZ in HLA-A*31:01 molecule has been postulated. 
 
5.7.3 Drug metabolism variants 
 Besides HLA gene, CYP2C9*2 and CYP2C9*3, a variant from cytochrome P450 
enzymes, a drug metabolizing enzyme, was associated with PHT-SJS/TEN. The 
association linked functionally to impairment in drug metabolism that caused delayed 
clearance of plasma phenytoin. The identification of patients with poor metabolizer 
variant can help prevent PHT toxicity and reduce risk of PHT-induced SCARs (Chung 
et al., 2014).  
 CYP2C9 genotypes were interpreted into phenotype predicting metabolizer 
status by Clinical Pharmacogenetics Implementation Consortium (CPIC) (cpicpgx.org). 
CPIC dosing recommendation linked CYP2C9 variants (CYP2C9*2 and CYP2C9*3) to 
phenytoin toxicity by categorised CYP2C9*2 and CYP2C9*3 genotype into 
intermediate (carrier with only one copy of *3 or *2) and poor metabolizer (carrier with 
two copy of *3 or *2) whereas carrier of two wildtype CYP2C9*1 alleles is considered 
extensive metabolizer (Caudle et al., 2014). PHT dosing is therefore recommended 
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based on metabolizer phenotype of either 25% (intermediate) or 50% (poor) reduction 
in recommended starting maintenance dose. CYP2C9*2 and *3 variants differ in 
different populations. In Han Chinese, allele frequency of CYP2C9*2 and *3 is 1% and 
5.5% respectively. While in Southern Indian, allele frequency of CYP2C9*2 is 2-5% 
and *3 is 10% (Caudle et al., 2014). The frequency is not known in Malay. However, 
due to small sample size in my PHT-SJS/TEN cohort (n=5; 1 Malay, 2 Chinese and 2 
Indians), CYP2C9*2 and *3 variant was not investigated in this study. 
 
5.8 Implication and future direction 
5.8.1 Implication of HLA association in CBZ-SJS/TEN 
 Due to high mortality, morbidity and long-term sequelae of SCARs, the goals in 
SCARs research is in prevention and exploring risk markers with strong predictive 
value for SCARs. The risk of aromatic antiepileptic drugs in causing SCARs affect 
many epilepsy treatment decision such as the choice of prescribed AEDs and how soon 
drug treatment is initiated. Therefore, evidence on association between HLA alleles 
(HLA-A*31:01 and HLA-B*15:02) that strongly predict SJS/TEN with high PPV and 
NNV have a profound effect on clinical practice.  
 Even though risk marker of HLA-B*15:02 for CBZ-SJS/TEN in Han Chinese 
and certain Asian populations have 100% negative predictive value, it is not generalized 
across other ethnicities such as Caucasian, Japanese and Koreans (Yip et al., 2012). 
Given the strong association of HLA-B*15:02 and CBZ-SJS/TEN in most Asia 
populations, screening prior to CBZ treatment is imperative. In Malaysia, HLA-B*15:02 
is a strong predictor for CBZ-SJS/TEN for all three major ethnic groups, Malay, 
Chinese and Indian. And HLA-B*15:02 screening prior to CBZ treatment is 
implemented in clinical practice. However, further study still need to be done on the 
factors that are important in ensuring HLA-B*15:02 screening is cost-effective and 
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implemented in clinical practice such as frequency of HLA-B*15:02 in other ethnic 
minority group, the disease prevalence of CBZ main indication, the rate of CBZ 
utilization and rapid detection time for HLA-B*15:02 test. 
 
5.8.2 Future direction 
 Recently, with even more alleles implicated with association to SJS/TEN 
induced by CBZ, PHT and LTG in different population, high resolution HLA genetic 
screening will be very much preferred in the future. However, that will be create more 
uncertainties which may make it difficult for clinician to decide suitable alternative 
AEDs. Such as the risk of SJS/TEN for a HLA-B*15:02 or HLA-A*31:01-positive 
patient started on other aromatic AEDs (OXC, LTG or PHT). If the patient is positive 
for one of the allele in HLA-B75 family that was implicated to associate with SJS/TEN, 
what is the risk of SJS/TEN and should CBZ be avoided. As such, studies on the 
pathogenesis on other HLA alleles implicated in SJS/TEN is needed to understand the 
association observed for these alleles and how drugs are capable of triggering T-cell 
immune response through these HLA molecules. 
 Although HLA screening has successfully utilized predictive risk marker into 
clinical practice, HLA mandatory screening has its pitfalls. If HLA-A*31:01 screening is 
to be implemented in clinical practice, further study on HLA test with short turnaround 
time (rapid test kit), policy adherence, and possible unintended knock-on effects will be 
needed. As exemplified in Hong Kong, mandatory screening of HLA-B*15:02 before 
CBZ treatment has led to the reduction in CBZ prescription and switching to other 
AEDs such as LTG and PHT that does not require pre-screening. Hence, although the 
incidence of CBZ-SJS/TEN decreased, the overall SJS/TEN incidence did not as patient 
was put on other AEDs associated with SJS/TEN that does not require screening (Chen 
et al., 2014a).  
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5.9 Study Limitation 
 Our data did not detect association of HLA-B*15:02 or other HLA-A or -B allele 
to PHT and LTG-induced SJS/TEN in all three ethnic groups. This is due to limited 
sample size, particularly after categorised into respective ethnic groups. As evidenced 
from other studies, the strength of association between HLA-B*15:02 and PHT/LTG-
induced SJS/TEN is weaker compared to CBZ-induced SJS/TEN. That is the same for 
AEDs-DRESS cases where there is only 3 (2 PHT-DRESS and 1 CBZ-DRESS). Given 
the small sample size in each of these group and taking into account the association is 
ethnicity-specific, further studies with larger sample size in each ethnic group will be 
needed to detect the association with sufficient power. 
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CHAPTER 6: CONCLUSION 
 
 The current study replicated and confirm the association between HLA-B*15:02 
and CBZ-SJS/TEN in Malay, Chinese and Indian populations in Malaysia. And a new 
association between HLA-A*31:01 and CBZ-SJS/TEN in Indians were also detected. 
Combining both HLA-A*31:01 and HLA-B*15:02 improve the predictive power in 
identifying patient with increased risk for CBZ-SJS/TEN. This is relevant for Indian 
population where HLA-B*15:02 frequency is lower and not homogeneous. This study’s 
findings also support clinical utility of HLA-A*31:01 screening and also added to the 
growing evidence on HLA-A*31:01 as a risk predictor for CBZ-SJS/TEN.  
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Appendix A: HLA-B alleles of AEDs-SCARs cases in Malay 
 
Malay HLA-B allele frequency in AEDs-SCARs cases 
HLA-B alleles Culprit drug SCARs Phenotype Allele frequency, % 
CBZ-SJS/TEN 
B*13:01 CBZ SJS/TEN 3.1 
B*15:01 CBZ SJS/TEN 3.1 
B*15:02 CBZ SJS/TEN 46.9 
B*15:12 CBZ SJS/TEN 3.1 
B*15:13 CBZ SJS/TEN 6.3 
B*15:18 CBZ SJS/TEN 3.1 
B*18:01 CBZ SJS/TEN 3.1 
B*18:02 CBZ SJS/TEN 3.1 
B*27:04 CBZ SJS/TEN 3.1 
B*35:05                       CBZ SJS/TEN 3.1 
B*37:01 CBZ SJS/TEN 3.1 
B*44:03 CBZ SJS/TEN 3.1 
B*46:01 CBZ SJS/TEN 3.1 
B*51:02 CBZ SJS/TEN 3.1 
B*58:01 CBZ SJS/TEN 3.1 
B*73:01 CBZ SJS/TEN 3.1 
PHT-SJS/TEN 
B*15:02                  PHT SJS/TEN 50.0 
B*15:21 PHT SJS/TEN 50.0 
LTG-SJS/TEN 
B*27:06 LTG SJS/TEN 50.0 
B*35:05 LTG SJS/TEN 50.0 
CBZ-DRESS 
B*15:02 CBZ DRESS 50.0 
B*18:01 CBZ DRESS 50.0 
PHT-DRESS 
B*15:02 PHT DRESS 50.0 
B*15:240 PHT DRESS 50.0 
 
CBZ-SJS/TEN cases, n=16 (2n=32) 
PHT-SJS/TEN cases, n=1 (2n=2) 
LTG-SJS/TEN cases, n=1 (2n=2) 
CBZ-DRESS cases, n=1 (2n=2) 
PHT-DRESS cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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Appendix B: HLA-B alleles of AEDs-SCARs cases in Chinese 
 
Chinese HLA-B allele frequency in AEDs-SCARs cases 
HLA-B alleles Culprit drug SCARs Phenotype Allele frequency, % 
CBZ-SJS/TEN 
B*13:01 CBZ SJS/TEN 8.3 
B*15:02 CBZ SJS/TEN 33.3 
B*27:04 CBZ SJS/TEN 8.3 
B*35:03 CBZ SJS/TEN 8.3 
B*38:02 CBZ SJS/TEN 8.3 
B*40:01 CBZ SJS/TEN 25.0 
B*44:02 CBZ SJS/TEN 8.3 
PHT-SJS/TEN 
B*13:01 PHT SJS/TEN 25.0 
B*46:01 PHT SJS/TEN 50.0 
B*51:01 PHT SJS/TEN 25.0 
LTG-SJS/TEN 
B*15:01 LTG SJS/TEN 50.0 
B*40:01 LTG SJS/TEN 50.0 
PHT-DRESS 
B*13:01 PHT DRESS 50.0 
B*73:01 PHT DRESS 50.0 
 
CBZ-SJS/TEN cases, n=6 (2n=12) 
PHT-SJS/TEN cases, n=2 (2n=4) 
LTG-SJS/TEN cases, n=1 (2n=2) 
PHT-DRESS cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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Appendix C: HLA-B alleles of AEDs-SCARs cases in Indians 
 
Indian HLA-B allele frequency in AEDs-SCARs cases 
HLA-B alleles Culprit drug SCARs Phenotype Allele frequency % 
CBZ-SJS/TEN 
B07:02 CBZ SJS/TEN 8.3 
B07:05 CBZ SJS/TEN 16.7 
B15:02 CBZ SJS/TEN 16.7 
B15:08 CBZ SJS/TEN 8.3 
B40:06 CBZ SJS/TEN 8.3 
B51:01 CBZ SJS/TEN 16.7 
B51:06 CBZ SJS/TEN 8.3 
B56:01 CBZ SJS/TEN 8.3 
B58:01 CBZ SJS/TEN 8.3 
PHT-SJS/TEN 
B*15:01 PHT SJS/TEN 25.0 
B*15:18 PHT SJS/TEN 25.0 
B*41:01 PHT SJS/TEN 25.0 
B*44:03 PHT SJS/TEN 25.0 
LTG-SJS/TEN 
B*44:03 LTG SJS/TEN 100.0 
 
CBZ-SJS/TEN cases, n=6 (2n=12) 
PHT-SJS/TEN cases, n=2 (2n=4) 
LTG-SJS/TEN cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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Appendix D: HLA-A alleles of AEDs-SCARs cases in Malays 
 
Malay HLA-A allele frequency in AEDs-SCARs cases 
HLA-A alleles Culprit drug SCARs Phenotype Allele frequency % 
CBZ-SJS/TEN 
A*01:01 CBZ SJS/TEN 6.3 
A*01:03 CBZ SJS/TEN 3.1 
A*02:01 CBZ SJS/TEN 12.5 
A*02:03 CBZ SJS/TEN 3.1 
A*02:07 CBZ SJS/TEN 3.1 
A*11:01 CBZ SJS/TEN 21.9 
A*11:02 CBZ SJS/TEN 3.1 
A*11:19 CBZ SJS/TEN 3.1 
A*24:02 CBZ SJS/TEN 9.4 
A*24:07 CBZ SJS/TEN 12.5 
A*24:10 CBZ SJS/TEN 6.3 
A*24:19 CBZ SJS/TEN 3.1 
A*33:03 CBZ SJS/TEN 6.3 
A*34:01 CBZ SJS/TEN 3.1 
A*74:01 CBZ SJS/TEN 3.1 
PHT-SJS/TEN 
A*24:02  PHT SJS/TEN 50.0 
A*34:01 PHT SJS/TEN 50.0 
LTG-SJS/TEN 
A*24:17 LTG SJS/TEN 50.0 
A*24:19 LTG SJS/TEN 50.0 
CBZ-DRESS 
A*11:01 CBZ DRESS 50.0 
A*24:02 CBZ DRESS 50.0 
PHT-DRESS    
A*11:01 PHT DRESS 50.0 
A*11:19 PHT DRESS 50.0 
 
CBZ-SJS/TEN cases, n=16 (2n=32) 
PHT-SJS/TEN cases, n=1 (2n=2) 
LTG-SJS/TEN cases, n=1 (2n=2) 
CBZ-DRESS cases, n=1 (2n=2) 
PHT-DRESS cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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Appendix E: HLA-A alleles of AEDs-SCARs cases in Chinese 
 
Chinese HLA-A allele frequency in AEDs-SCARs cases 
HLA-A allele Culprit drug SCARs Phenotype Allele frequency % 
CBZ-SJS/TEN 
A*02:03 CBZ SJS/TEN 16.7 
A*02:06 CBZ SJS/TEN 8.3 
A*11:01 CBZ SJS/TEN 25.0 
A*11:04 CBZ SJS/TEN 8.3 
A*11:117 CBZ SJS/TEN 8.3 
A*11:19 CBZ SJS/TEN 8.3 
A*24:02 CBZ SJS/TEN 8.3 
A*24:46 CBZ SJS/TEN 8.3 
A*32:01 CBZ SJS/TEN 8.3 
PHT-SJS/TEN 
A*02:03 PHT SJS/TEN 25.0 
A*02:114 PHT SJS/TEN 25.0 
A*02:447 PHT SJS/TEN 25.0 
A*11:10 PHT SJS/TEN 25.0 
LTG-SJS/TEN 
A*11:01 LTG SJS/TEN 50.0 
A*24:02 LTG SJS/TEN 50.0 
PHT-DRESS 
A*01:06 PHT DRESS 50.0 
A*02:142 PHT DRESS 50.0 
 
CBZ-SJS/TEN cases, n=6 (2n=12) 
PHT-SJS/TEN cases, n=2 (2n=4) 
LTG-SJS/TEN cases, n=1 (2n=2) 
PHT-DRESS cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
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Appendix F: HLA-A alleles of AEDs-SCARs cases in Indians 
 
Indian HLA-A allele frequency in AEDs-SCARs cases 
HLA-A alleles Culprit drug SCARs Phenotype Allele frequency % 
CBZ-SJS/TEN 
A02:01 CBZ SJS/TEN 8.3 
A02:06 CBZ SJS/TEN 16.7 
A02:11 CBZ SJS/TEN 16.7 
A03:01 CBZ SJS/TEN 8.3 
A11:01 CBZ SJS/TEN 8.3 
A24:17 CBZ SJS/TEN 8.3 
A31:01 CBZ SJS/TEN 25.0 
A33:03 CBZ SJS/TEN 8.3 
PHT-SJS/TEN 
A*23:14 PHT SJS/TEN 25.0 
A*33:03 PHT SJS/TEN 25.0 
A*36:04 PHT SJS/TEN 25.0 
A*68:01 PHT SJS/TEN 25.0 
LTG-SJS/TEN 
A*33:03 LTG SJS/TEN 100.0 
 
CBZ-SJS/TEN cases, n=6 (2n=12) 
PHT-SJS/TEN cases, n=2 (2n=4) 
LTG-SJS/TEN cases, n=1 (2n=2) 
 
AEDs, antiepileptic drugs; SCARs, severe cutaneous adverse reactions; SJS, Steven-
Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, Drug reaction with 
eosinophilia and systemic symptoms; CBZ, Carbamazepine; PHT, Phenytoin; LTG, 
Lamotrigine 
 
 
 
 
	
